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INTRODUCTION 
 
 
Living organisms require a relatively steady energy supply to sustain biological 
functions. Moreover, energy reserves must not only be sufficient to serve all 
physiological needs, but must also be wisely allocated to a wide variety of 
often competing physiological functions (1). Energy intake and energy 
expenditure undergo substantial daily and seasonal fluctuations, however.  
Immunity requires adequate and balanced energy supply for optimal function 
(2). Although the risk of infection and death is highest when energy reserves 
are not sufficient (3), obesity, a state of energy excess, has also been associated 
with increased susceptibility to infection, bacteremia, and poor wound healing 
(4).  
The discovery of the adipocyte-derived hormone leptin, the levels of which 
reflect the amount of energy stored in the adipose tissue and are altered by 
conditions such as fasting and overfeeding, has proved to be fundamental to our 
understanding of the concept of energy availability influencing several 
physiological systems. More specifically, the past few years of research on 
leptin — the product of the obese (ob) gene — have provided important 
insights into the intricate network that links nutrition, metabolism and immune 
homeostasis (5). Leptin is mainly produced by the adipose tissue in proportion 
to the body fat mass and, at lower levels, by tissues such as the stomach, 
skeletal muscle and placenta (5). Although an important role of leptin is to 
regulate body weight through the inhibition of food intake and stimulation of 
energy expenditure by increased thermogenesis, recent evidence has indicated 
that leptin is much more than a 'fat-o-stat' sensor (6). Indeed, leptin-deficient 
(ob/ob) mice and leptin-receptor-deficient (db/db) mice are not only severely 
obese, but also have a series of marked abnormalities that are secondary to the 
effects of leptin on reproduction (7), haematopoiesis (8), angiogenesis (9,10), 
insulin secretion (5), metabolism of bone (11), lipids and glucose (1) and, last 
but not least, innate and adaptive immunity. 
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Leptin as a neuroendocrine and immune mediator 
 
Leptin is a 16-kDa nonglycosylated protein encoded by the obese (ob) gene, 
which is located on human chromosome 7 and on mouse chromosome 6 (5). In 
both humans and mice, mutations of the ob gene are associated with 
hyperphagia and obesity, reduced energy expenditure, and other reproductive, 
neuroendocrine, and metabolic dysfunction. Serum leptin is usually higher in 
obese individuals and has a strong sexual dimorphism, being higher in females 
than males matched by age and body weight (5). 
Leptin is classically considered a hormone because it regulates the balance 
between food intake and energy expenditure, signalling to the brain the 
changes in stored energy. Synthesized primarily by the white adipose tissue, 
leptin is secreted at lower levels by the gastric mucosa, placenta, mammary 
epithelium, and skeletal muscle (5). Leptin gene expression is regulated by 
several factors, including other hormones. Insulin stimulates leptin secretion 
during feeding, while a decrease in insulin levels anticipates a fall in leptin 
during starvation (5). Moreover, leptin expression is inhibited by testosterone, 
increased by ovarian sex steroids, and directly influences the hypothalamic-
pituitary-adrenal axis, the reproductive system, hematopoiesis, and 
angiogenesis (5).  
Many studies have linked the immune and neuroendocrine systems (12, 13). 
Physiological responses to stress usually involve finely integrated interactions 
between the autonomic nervous system and the HYPOTHALAMO-
PITUITARY-ADRENAL (HPA) AXIS, and the immune system and 
metabolism (12, 13). For example, peripheral inflammation stimulates the 
central release of corticotrophin-releasing hormone (CRH), which in turn 
regulates the stress response through the production of adrenocorticotrophic 
hormone (ACTH) — a hormone that promotes the synthesis and release of 
GLUCOCORTICOIDS from the adrenal glands. The glucocorticoids — 
hormones that get their name from their ability to raise levels of blood glucose 
— have potent anti-inflammatory effects and dampen humoral and cell-
mediated immune responses. 
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Interestingly, mediators that are common to the neuroendocrine and immune 
systems, such as the cytokines interleukin-1 (IL-1), IL-6 and tumour-necrosis 
factor (TNF), can all modulate inflammation through the HPA axis (12, 13). 
Indeed, these peripherally derived cytokines can cross the blood–brain barrier 
and act on the hypothalamus and pituitary gland to regulate the secretion of 
ACTH in response to inflammation. These cytokines also mediate a negative 
feedback on their own peripheral pro-inflammatory activity and are counter-
regulated by endogenous glucocorticoids produced by the HPA axis. 
Leptin is one of the mediators that are common to the neuroendocrine and 
immune systems (14). In the immune system, leptin, together with C-
REACTIVE PROTEIN (CRP), IL-1 and IL-6, can act as an early acute-phase 
reactant, produced at high levels during inflammation, sepsis and fever, and it 
can be induced by other inflammatory mediators such as TNF and IL-1 (15-
21). However, although these findings have been demonstrated in several 
systems, other studies have not found increased leptin in inflammatory 
conditions in humans, including acute experimental endotoxaemia, newborn 
sepsis, HIV infection and during anti-inflammatory therapy (22-24). So, 
although leptin has well documented pro-inflammatory properties, it seems that 
it might act as an acute-phase reactant in some conditions and not in others. 
The neuroendocrine role of leptin is most evident in conditions such as fasting 
— during which the production of leptin by adipose tissue is markedly reduced 
— or in relation to the effects of sex hormones on its production (testosterone 
reduces the secretion of leptin, whereas oestrogens increase its production). 
The link between leptin and sex hormones is also indicated by the marked 
gender dimorphism, manifested by a higher serum concentration in females 
than in males with similar body fat mass. 
The fact that leptin has effects on both the neuroendocrine and immune 
systems should not come as a surprise, given the functional connection and 
anatomical contiguity between adipocytes and lymphoid cells (6). 
Morphologically, aggregations of lymphoid tissue, including the lymph nodes, 
omentum, thymus and bone marrow, are associated with adipose tissue (6). Fat 
deposits do not simply have a structural, metabolic and heat-insulating 
function, but provide a microenvironment that helps the immune system to 
sustain immune responses (6). In particular, lymphoid and adipose tissue 
 6
interact locally through common mediators known as adipokines — adipocyte-
derived molecules that bridge metabolism and immune homeostasis (these 
molecules include leptin, adiponectin, chemokines and other pro-inflammatory 
cytokines). For example, TNF and chemokines promote the differentiation of 
adipose tissue and leptin secretion, which in turn sustains the differentiation of 
T helper 1 (TH1) cells (see later) (25, 26). 
 
 
Leptin signalling in immune cells   
 
Leptin, as previously mentioned, is mainly secreted by the adipose tissue, 
which is also present within both primary and secondary lymphoid organs and 
has a significant metabolic and immunomodulatory role (27, 28). Leptin’s 
three-dimensional structure is similar to that of a cytokine consisting of a four 
-helix bundle motif (which is common to the IL-6, IL-12, IL-15 family of 
cytokines) (29). Leptin receptor (ObR), is also a member of the class I cytokine 
receptor superfamily and has at least six isoforms as a result of alternative 
splicing with cytoplasmatic domains of different length, known as OBRa, 
OBRb, OBRc, OBRd, OBRe and OBRf (30, 31). These receptors are 
membrane-spanning glycoproteins with fibronectin type III domains in the 
extracellular region and with a shared 200-amino-acid module containing four 
conserved cysteine residues and two membrane proximal cytokine-like binding 
motifs, Trp-Ser-Xaa-Trp-Ser (30, 31). The short forms of the leptin receptor 
are expressed by several non-immune tissues and seem to mediate the transport 
and degradation of leptin. The long form of OBR, known as OBRb, is the only 
form able to transduce the signal and is expressed by the hypothalamus in areas 
that are responsible for the secretion of neuropeptides and neurotransmitters 
that regulate appetite, body weight (30, 31) and bone mass (11). Interestingly, 
OBRb is also expressed by endothelial cells, pancreatic β-cells, the ovary, 
CD34+ haematopoietic bone-marrow precursors, monocytes/macrophages, and 
T and B cells (5, 9,10, 30, 31). The expression of OBRb by T and B cells is of 
interest as it indicates a possible role for leptin in immune-cell activation and 
signal transduction, and might unveil new effects of leptin on as-yet-
unexplored immune-cell functions (32, 33, 34). After binding leptin, OBRb-
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associated Janus-family tyrosine kinase 2 (JAK2) becomes activated by auto- 
or cross-phosphorylation and tyrosine phosphorylates the cytoplasmic domain 
of the receptor. Four of the phosphorylated tyrosine residues function as 
docking sites for cytoplasmic adaptors such as signal transducer and activator 
of transcription (STAT) factors, particularly STAT3 (in some cases, also 
STAT1 and STAT5) (30-34) (figure 1).  
 
 
Fig.1 Schematic representation of leptin signalling 
 
 
The membrane distal tyrosine (position 1138) functions as a docking site for 
STAT3, which is a substrate of JAK2. After subsequent dimerization, STAT3 
translocates to the nucleus and induces the expression of suppressor of 
cytokine signalling 3 (SOCS3) and other genes. SOCS3 takes part in a 
feedback loop that inhibits leptin signalling by binding to phosphorylated 
tyrosines. SRC homology 2 (SH2) domain-containing phosphatase 2 (SHP2) is 
recruited to Tyr985 and Tyr974, and activates extracellular signal-regulated 
kinase 1/2 (ERK1/2) and p38 mitogen-activated protein kinase (MAPK) 
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pathways through the adaptor protein growth factor receptor-bound protein 2 
(GRB2), ultimately inducing the expression of FOS and JUN (30-37). After 
leptin binding, JAK2 can induce phosphorylation of the insulin receptor 
substrate 1/2 (IRS1/2) proteins that are responsible for the activation of 
phosphatidylinositol 3-kinase (PI3K) (30-37) (figure 1).  Moreover, Src 
associated in mitosis protein (Sam68), an RNA-binding protein, regulator of 
RNA metabolism and effector of the PI3'K is currently thought to function as 
an adaptor protein by binding to activated STAT-3 and to the p85 subunit of 
PI3'K (35) Phosphotyrosine phosphatase 1B (PTP1B), which is localized on 
the surface of the endoplasmic reticulum, is involved in negative regulation of 
OBRb signalling through the dephosphorylation of JAK2 after internalization 
of the OBRb complex. 
 
 
Leptin in innate and adaptive immunity 
 
Mice lacking leptin or its functional receptor have a number of defects in both 
cell-mediated and humoral immunity (38, 39). Similarly, humans with 
congenital leptin deficiency have a much higher incidence of infection-related 
death during childhood (40), whereas recombinant human leptin 
(rmetHuLeptin) administration in two children with congenital leptin 
deficiency normalized absolute numbers of naive CD4+CD45+RA T cells and 
nearly restored the proliferation response and the cytokine release profile from 
their lymphocytes (41). A number of studies in mice have shown that the effect 
of leptin on the immune system is both direct and indirect, i.e., via modulation 
of central or peripheral pathways (42, 43) (figure 2). Leptin seems to promote 
activation of and phagocytosis by monocytes/macrophages and their secretion 
of leukotriene B4 (LTB4), cyclooxygenas 2 (COX2), nitric oxide and pro-
inflammatory cytokines (44-46). The products of the inducible form of COX2 
— prostaglandins and leukotrienes (also known as eicosanoids) — as well as 
nitric oxide, are all involved in the regulation of inflammation, chemotaxis and 
cytokine production, and therefore markedly impact the immune response (44-
46). Moreover, leptin can induce chemotaxis of neutrophils and the release of 
oxygen radicals (such as superoxide anion and hydrogen peroxide) (47, 
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48).These mediators can be particularly harmful to cells, as they can denature 
proteins and damage membrane lipids (by peroxidation of unsaturated fatty 
acids), carbohydrates and nucleic acids. At least in human neutrophils, leptin 
seems to mediate its effects through an indirect mechanism, probably involving 
the release of TNF from monocytes (49). Leptin also affects natural killer 
(NK)-cell development and activation both in vitro and in vivo (50-52). As NK 
cells express OBRb and db/db mice have a deficit of NK cells resulting from 
abnormal NK-cell development, it is possible that leptin might influence the 
development/maintenance of a normal peripheral NK-cell pool. Indeed, an 
important role of OBRb in NK-cell physiology is indicated by the ability of 
OBRb to influence NK-cell cytotoxicity through direct activation of signal 
transducer and activator of transcription 3 (STAT3) and the transcription of 
genes encoding IL-2 and perforin (50-52) . 
  
 
      Fig.2  Schematic representation of the effects of leptin on both innate and adaptive immunity.  
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Last but not least, it has recently been shown that leptin can stimulate the 
production of growth hormone by peripheral-blood mononuclear cells 
(PBMCs) through protein kinase C (PKC)- and nitric oxide-dependent 
pathways (46).This effect of leptin on the production of growth hormone might 
be important in immune homeostasis, given the fact that this cytokine-like 
hormone has marked influences on immune responses by controlling the 
survival and proliferation of immue cells(46).  
The effects of leptin on adaptive immune responses have been extensively 
investigated on human CD4+ T cells (figure 2). Addition of physiological 
concentrations of leptin to a Mixed Lymphocytes Reaction (MLR) induces a 
dose-dependent increase in CD4+ T-cell proliferation. However, leptin has 
different effects on proliferation and cytokine production by human naive 
(CD45RA+) and memory (CD45RO+) CD4+ T cells (both of which express 
OBRb). Leptin promotes proliferation and IL-2 secretion by naive T cells, 
whereas it minimally affects the proliferation of memory cells (on which it 
promotes a bias towards TH1-cell responses) (53). Furthermore, leptin 
increases the expression of adhesion molecules, such as intercellular adhesion 
molecule 1 (ICAM1, CD54) and very late antigen 2 (VLA2, CD49B), by 
CD4+ T cells, possibly through the induction of pro-inflammatory cytokines 
such as interferon-γ (IFN-γ). Increased expression of adhesion molecules could 
then be responsible for the induction of clustering, activation and migration of 
immune cells to sites of inflammation (53). Another important role of leptin in 
adaptive immunity is highlighted by the observation that leptin deficiency in 
ob/ob mice is associated with immunosuppression and thymic atrophy — a 
finding similar to that observed in acute starvation. Acute caloric deprivation 
causes a rapid decrease of serum leptin concentration accompanied by reduced 
Delayed-Type-Hypersensitivity (DTH) responses and thymic atrophy, which 
are reversible with administration of leptin (54, 55). The thymic atrophy in 
ob/ob mice (or wild-type starved animals) affects the cortex of the thymus, in 
which most CD4+CD8+ T cells are found, and leptin replacement reduces the 
rate of apoptosis of such cells (54). Despite the evidence of direct effects of 
leptin on immune responses in vitro, a major problem remains in ascertaining 
whether leptin can influence immune responses in vivo. This task is particularly 
difficult because of the complexity of the network of interactions that link 
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leptin to several endocrine pathways. For example, the immune abnormalities 
associated with high cortisol levels and hyperglycaemia in obese ob/ob or 
db/db mice could simply be a consequence of obesity rather than direct effects 
of leptin (55). To help clarify this issue, studies of food restriction, which can 
reduce cortisol and glucose levels in ob/ob mice, have shown that only leptin 
replacement can fully restore normal immune responses in ob/ob mice, 
whereas experimentally induced reduction of serum levels of cortisol and 
glucose cannot reverse immune abnormalities (55). Although still 
controversial, these observations seem to indicate that the immune 
abnormalities in ob/ob mice cannot be simply ascribed to high circulating 
levels of cortisol and glucose, and that leptin might instead have direct effects 
on the immune system that are independent of the metabolic abnormalities 
associated with leptin deficiency (55).  
 
 
Regulatory T cell 
 
The immune system has devised many checks and balances to circumvent 
autoimmune disease. Those mechanism have been broadly categorized as 
influencing central or peripheral tolerance, each having a nonredundant 
function in maintaining antigen-receptor diversity while providing safeguards 
to effectively curtail self-reactivity. Peripheral tolerance to self was suggested 
several years ago to result from the induction of anergy in peripheral self-
reactive lymphocytes. More recently, however, it has become clear that 
avoidance of damage to the host is also achieved by active suppression 
mediated by regulatory T cell (Tregs) populations. 
The CD4+CD25+ T cell subset is currently the focus of intensive research. TRegs 
are known to dampen autoreactive responses mediated by CD4+CD25– T cells 
and may influence the onset and progression of autoimmunity (56). In mice, 
depletion of TRegs is associated with autoimmunity, and defects of TRegs have 
been described in nonobese diabetic mice and in humans with type 1 diabetes 
(56, 57).  These cells represent 5−10% of the CD4+ T lymphocytes in healthy 
adult mice and humans and are thought to perform a specialized role in 
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controlling both the innate and the adaptive immune system (58-60) and 
exhibit a vast spectrum of autoimmunity-preventive activity.  
The important issue of the mechanisms of suppressive action by Treg cells 
remains unresolved. Although in vitro suppression is contact-dependent and is 
insensitive to transforming growth factor-β (TGF-β) or IL-10 blockade, both 
IL-10 and TGF-β have been linked to suppression mediated by Treg cells in 
several in vivo experimental models (61, 62). Reverse signalling through cross-
linking of B7 (CD80 and CD86) on the cell surface of antigen-presenting cells 
or activated T cells, mediated by cytotoxic T lymphocyte–associated antigen 4 
(CTLA-4) expressed by Treg cells, has been proposed as yet another effector 
mechanism of suppression (63). However, like IL-10 and TGF-β, CTLA-4 
does not seem to be a non-redundant mechanism of suppression, as Treg cells 
isolated from mice with the targeted deletions of genes encoding each of these 
molecules are suppressive in vitro (64, 65). The interplay of these mechanisms 
in Treg cell function in vivo remains to be further defined. In addition, after 
activation, human Treg cells may directly kill activated CD4 and CD8 T cells 
in a perforin- or granzyme-dependent way (66). Finally, it has been proposed 
that Treg cells may suppress immune activation by ‘soaking up’ T cell growth 
factors such as IL-2 (67). It is likely the predominant effector mechanism of 
Treg cell–mediated suppression may vary depending on the specific tissue and 
inflammation type being studied. Treg cell–specific gene targeting may help to 
elucidate the suppressive mechanisms operating in vivo. 
As for the involvement of cytokines in affecting suppressive properties of Treg 
cells, early reports indicated that Treg cell–mediated in vitro suppression could 
be overridden by provision of large amounts of IL-2 (59). However, more 
recent studies have suggested that Treg cells are capable of suppressing IL-2 
mRNA induction in responder cells even in the presence of large amounts of 
IL-2 (68). Moreover, two groups have reported that Treg cell suppressive 
activity in vitro is dependent on IL-2, as it is abrogated in the presence of IL-2-
neutralizing antibodies (68, 69). Those data and results, suggesting that the 
maintenance of CD25 expression on Treg cells depends on IL-2 (70) envision 
the possibility of a relatively simple regulatory network whereby the 
maintenance and suppressive activity of Treg cells is conditional on IL-2 
production by non-regulatory T cells. Furthermore, increased amounts of IL-2 
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resulting from immune activation may fuel the expansion of the Treg cell 
population. 
Although CD25 expression has been useful in defining the Treg cell 
population in non-immune mice and humans, accurate discrimination between 
Treg cells and recently activated non-regulatory T cells, which up-regulate 
CD25, during immune activation, associated with autoimmune pathology or 
infection, is almost impossible. Increased expression of CD25, as well as 
GITR, CTLA-4 and lymphocyte activation gene 3, on activated non-regulatory 
T cells suggests that expression of these molecules does not functionally define 
the Treg cell population and raises the possibility that not all Treg cells express 
these molecules. Therefore, a principal challenge is to identify a unique 
functional molecular marker of Treg cells. The identification of such a 
molecule should help to resolve a fundamental issue regarding the nature of 
dominant tolerance. Two general models for T cell–mediated 
immunosuppression have been considered: that Treg cells represent a dedicated 
functional lineage, or that Treg cells represent a ‘plastic’ phenotype. The first 
model suggests the existence of a factor responsible for specifying a Treg cell 
lineage, which therefore serves as the mediator of the genetic mechanism of 
dominant tolerance. The second argues that T cell–mediated 
immunosuppression is not the purview of a dedicated Treg cell lineage but is 
the consequence of a dynamic balance between cells expressing different 
amounts of cytokine receptors and different cytokine production profiles (71).  
The forkhead/winged helix transcription factor Foxp3 was shown to be 
specifically expressed by CD25+ Tregs cells, as well as by CD25- T cells with 
regulatory activity (72-74). This transcription factor is though to program the 
development and function of this subset and so far is the most unambiguous 
marker available to identify naturally occurring Tregs cells.  
Foxp3 belongs to a large family of functionally diverse transcription factors 
based on its winged helix–forkhead DNA-binding domain (forkhead box (Fox). 
In addition to the C-terminal forkhead domain, Foxp3 also  contains a 
Cys2His2 zinc finger domain and a coiled-coil–leucine zipper motif. 
Homology among full-length human, mouse and rat Foxp3 is very high, 
suggesting a highly conserved function. At present there is very little 
understanding of the function of Foxp3 at the molecular level. Foxp3 binds 
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DNA, localizes to the nucleus and can act as a transcriptional repressor (75). 
Identification of consensus forkhead binding domains adjacent to NFAT 
transcription factor binding sites in the promoters of several cytokine genes, 
including those encoding IL-2, IL-4 and tumor necrosis factor, led to the 
proposal of a model of Foxp3-mediated transcriptional inhibition or repression 
in which Foxp3 antagonizes NFAT function by competition for DNA binding 
sites (75). Based on those and other studies, it has also been proposed that 
Foxp3 is induced in a variety of cell types as a general mechanism of negative 
immune regulation by repressing production of inflammatory cytokines. 
However, so far there has been no characterization of Foxp3 target genes or the 
transcriptional program specified by Foxp3. 
Loss-of –function mutations in this gene, in both humans and mice, caused the 
absence of Tregs cells (see fatal human autoimmune disorder ‘immune 
dysregulation, polyendocrinopathy, enteropathy, X-linked’ (IPEX). 
Furthermore, transgene-driven Foxp3 overexpression in mice results in an 
increase in the CD4+CD25+ Treg cell subset and acquisition of suppressive 
properties by CD4+CD25– and CD8+ T cells, although these cells are not as 
efficient at inhibiting CD25–CD4+ T cell in vitro responses as are 
CD4+CD25+ Treg cells (73). 
Precise signals that promote the development of Treg cells remain elusive, but 
considerable evidence suggests that costimulatory molecules and cytokines 
play important roles (76-79). Depending on these additional signals, 
thymocytes are then either negatively selected or induce a genetic program for 
Treg cells, including up-regulation of Foxp3 and CD25. Other mechanisms 
suggested that something about the nature of the TCR, including its affinity for 
ligand and/or the level of expression, instructs the cells to become Treg cells 
(80-83). On the other hand van Santen et al. (84) suggested that perhaps the 
niche or the context in which the T cell encounters antigen in the thymus is 
more important than affinity in determining cell fate. 
Analysis of TCR from Treg cells has demonstrated that a large proportion of 
this population has a higher avidity to self-antigen in comparison with TCR 
from CD4+CD25- cells (82) and that peripheral antigen is required for their 
development, maintenance, or expansion. Treg cells have been shown to 
undergo expansion in the periphery, likely regulated by the presence of self-
 15
antigen (85, 86). Neonatally thymectomized mice, which are deficient in Treg 
cells, develop multiorgan autoimmune disease, which can be overcome by the 
adoptive transfer of this population of T cells from normal mice. Several 
clinical observations in humans have supported a link between reduced thymic 
function, with impaired Treg cell generation, and the induction of autoimmune 
diseases, suggesting a central role for these cells in self-tolerance (87).  
 
 
 
 
Figure 3. CD4+CD25+ T cells seem to be members of a unique lineage of T cells that are selected during 
the process of T-cell differentiation in the thymus. It remains unclear where and when this occurs. A)  
One possibility is that CD25+ T cells acquire expression of CD25 and suppressor function in the thymic 
medulla, where they recognize self-antigens that are presented on MHC class II molecules by medullary 
dendritic cells (DCs) in a process that is known as 'altered negative selection'. They then migrate directly 
to peripheral lymphoid tissues. B) Studies with the K14 transgenic mouse have indicated that CD25 
expression and suppressor function is acquired at a much earlier stage of differentiation in the thymic 
cortex during the process of positive selection on cortical epithelial cells. Some of these CD25+ T cells 
then undergo a process of negative selection on bone-marrow-derived cells (such as DCs) in the medulla 
and die by apoptosis, but others are allowed to migrate to peripheral lymphoid tissues, according to the 
affinity of their TCR for self-antigens. TCR, T-cell receptor; Ts, suppressor T cell. 
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Leptin in Autoimmunity  
 
As mentioned earlier, ob/ob mice have several abnormalities that are common 
to starved animals (5). However, ob/ob (and db/db) mice also have additional 
endocrine and metabolic disturbances that could affect the immune system 
indirectly, such as hypercorticosteronaemia and diabetes (5). Similarly, 
starvation not only associates with hypoleptinaemia, but also with an increased 
concentration of glucocorticoids and decreased levels of thyroid and growth 
hormones (which can result in immune suppression) (5). So, the effects of 
leptin on the immune system should take into account both the direct and 
indirect effects of this molecule on other hormones. Although the influence of 
thyroid and growth hormones on the effects of leptin remains elusive, it seems 
that leptin can affect thymic output and T-cell function independently of 
glucocorticoids, as congenitally leptin-deficient individuals have 
glucocorticoid levels within a normal range, but markedly reduced numbers of 
naive T cells (5).  
More importantly, ob/ob mice have reduced secretion of IL-2, IFN-γ, TNF and 
IL-18, and increased production of TH2-type cytokines, such as IL-4 and IL-10, 
after mitogenic stimulation. As a result, ob/ob mice are resistant to the 
induction of several experimentally induced autoimmune diseases, for 
example, AIA (ANTIGEN-INDUCED ARTHRITIS), which is a model of 
immune-mediated joint inflammation induced by administration of methylated 
bovine serum albumin (mBSA) into the knees of immunized mice (88). The 
severity of arthritis in leptin and leptin-receptor-deficient mice was reduced. 
The milder form of AIA seen in ob/ob and db/db mice, as compared with 
controls, was accompanied by decreased synovial concentrations of IL-1β and 
TNF-α (Th1-type cytokines), decreased in vitro proliferative response to 
antigen in lymph node cells, and a switch toward the production of Th2 
cytokines (88). Serum levels of anti-mBSA antibodies were also significantly 
decreased in the arthritic  ob/ob mice, as compared with controls. 
Thus, in AIA, leptin may probably contribute to joint inflammation by 
regulating both humoral and cell-mediated immune responses. However, joint 
inflammation in AIA depends on adaptive immune responses, which are 
impaired in ob/ob and db/db and mice. More recent studies have investigated 
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the effect of leptin and leptin receptor deficiency on the inflammatory events of 
zymosan-induced arthritis (ZIA), a model of proliferative arthritis restricted to 
the joint injected with zymosan A and not dependent on adaptive immune 
responses (89). ZIA, in contrast to AIA, was not impaired in ob/ob and db/db 
mice. However, the resolution of acute inflammation was delayed in the 
absence of leptin or leptin signaling, suggesting that leptin could exert 
beneficial influences on the evolution of this model of arthritis (90). 
In humans, patients with rheumatoid arthritis (RA) with reduced serum leptin 
levels induced by fasting reportedly had improved clinical and biological 
measures of disease activity associated with a decrease of CD4+ lymphocyte 
activation and a shift toward Th2 cytokine production (91). These aspects, 
resembling somehow those seen in AIA in ob/ob mice, suggested that leptin 
could also influence inflammatory arthritis in humans through an influence on 
Th1 responses.  
Ob/ob mice are also protected from EXPERIMENTAL AUTOIMMUNE 
ENCEPHALOMYELITIS (EAE), whereas administration of leptin to 
susceptible wild-type mice worsens EAE by increasing the secretion of pro-
inflammatory cytokines and directly correlates with pathogenic T-cell 
autoreactivity (see later for further details). Protection of ob/ob mice from 
autoimmunity is also observed in EXPERIMENTALLY INDUCED 
HEPATITIS (EIH) (91, 92). Activation of T cells and macrophages is one of 
the initial events during viral or autoimmune hepatitis. Activated T cells are 
directly cytotoxic for hepatocytes and release proinflammatory cytokines, 
which mediate hepatocyte damage. A well-described mouse model of T-cell-
dependent liver injury is the one induced by i.v. injection of the T cell mitogen 
concanavalin A (Con A), which results in fulminant hepatitis. During Con-A-
induced hepatitis, TNF-α is a crucial cytokine in the acute disease process 
because neutralization of this cytokine reduces liver damage. On the other 
hand, the injection of TNF-α causes acute inflammatory hepatocellular 
apoptosis followed by organ failure, and TNF-α thus appears to cause 
hepatoxicity. Siegmund et al. (92) showed that leptin-deficient ob/ob mice 
were protected from Con-A-induced hepatitis. TNF-α and IFN-γ levels, as well 
as expression of the activation marker CD69, were not elevated in ob/ob mice 
following administration of Con A, suggesting that their resistance was 
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associated with reduced levels of those proinflammatory cytokines, together 
with low percentages of intrahepatic NKT cells (which are cells that contribute 
to progression of this disease) (92). Similar results were obtained in EIH 
induced by Pseudomonas aeruginosa exotoxin A administration (91). Also in 
this case, leptin administration restored responsiveness of ob/ob mice to EIH, 
and T lymphocytes and TNF-α were required for the induction of liver injury. 
The authors also showed that leptin played an important role in the production 
of two proinflammatory cytokines in the liver, namely TNF-α and IL-18 (91). 
Finally, ob/ob mice are resistant to acute and chronic intestinal inflammation 
induced by dextran sodium sulphate and to colitis induced by trinitrobenzene 
sulphonic acid (EXPERIMENTALLY INDUCED COLITIS, EIC) (93).In 
acute EIC, ob/ob mice do not develop intestinal inflammation and show 
decreased secretion of pro-inflammatory cytokines and chemokines. As 
expected, leptin replacement increases cytokine production to the levels 
observed in control mice (93). Of interest, recent reports have shown that leptin 
secreted by the gastric mucosa is not completely degraded by proteolysis and 
can therefore reach the intestine in an active form, where it can control the 
expression of sodium/glucose and peptide transporters on intestinal epithelial 
cells (94, 95). As a result, leptin might have a dual nature: on one hand, leptin 
could function as a growth factor for the intestine, because of its involvement 
in the absorption of carbohydrates and proteins; on the other hand, leptin could 
function as a mediator of intestinal inflammation (93-95). 
More recently, protection from autoimmunity in ob/ob mice has been observed 
in EXPERIMENTALLY INDUCED GLOMERULONEPHRITIS (96). In this 
immune-complex-mediated inflammatory disease induced by injection of 
sheep antibodies specific for mouse glomerular basement membrane into mice 
preimmunized against sheep IgG, the authors observed renal protection of 
ob/ob mice associated with reduced glomerular crescent formation, reduced 
macrophage infiltration, and glomerular thrombosis. These protective effects 
were associated with concomitant defects of both adaptive and innate immune 
response (testified by reduced in vitro proliferation of splenic T cells and 
reduced humoral responses to sheep IgG, respectively). Finally, evidence that 
leptin may exert pathogenic effects in immune-mediated disorders of the 
kidney come from the finding that leptin is a renal growth and profibrogenic 
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factor that contributes to endocapillary proliferation and subsequent 
development of glomerulosclerosis during renal damage in conditions possibly 
including diabetes and obesity, both characterized by high circulating leptin 
levels (97). 
All these studies concern a role for leptin in experimentally “induced” 
autoimmunity. However, leptin is also important in “spontaneous” autoimmune 
DIABETES in non-obese diabetic (NOD) mice (98). Leptin accelerates 
autoimmune diabetes in females NOD/LtJ mice (99, 100). Fluctuations in 
serum leptin levels have been also observed in a study performed by our group 
in an animal model of CD4+ T cell-mediated autoimmune disease, such as type 
1 diabetes (T1D). Non-obese diabetic (NOD/LtJ) female mice, spontaneously 
prone to the development of beta-cell autoimmunity, have higher serum leptin 
levels, as compared to NOD/LtJ males and non-susceptible strains of mice, and 
show a serum leptin surge preceding the appearance of hyperglycaemia (99). 
Furthermore, early in life leptin administration significantly anticipated the 
onset of diabetes and increased mortality and inflammatory infiltrates in beta-
islets; this phenomenon correlated with increased secretion of IFN-γ in leptin-
treated NOD mice (99). More recently, it has been found that a natural leptin 
receptor mutants of the NOD/LtJ strain of mice (named NOD/LtJ-db5J) display 
reduced susceptibility to T1D (101, 102). These data further support the role of 
leptin in the pathogenesis of T1D. These NOD-db5J mice are obese, 
hyperphagic and show hyperglycaemia associated with hyperinsulinaemia. The 
leptin receptor mutation affects the extracellular domain  of the leptin receptor 
probably impairing the leptin-binding and/or receptor dimerization. This effect 
is likely able to alter the intracellular signalling machinery, thus impairing the 
pathogenicity of anti-islets autoreactive T cells. Indeed, these mice show mild-
low grade infiltration of the islets. This model nicely complements the 
previously published data from our group, hypothesizing a key role for leptin 
in the development of T1D. Further studies are needed to address the molecular 
machinery determining the phenotype of resistance observed in these mice as 
well as the possibility to interfere with T1D pathogenesis by blocking the leptin 
axis. 
Another indication that leptin could be involved in autoimmunity is the sexual 
dimorphism of serum leptin concentration (higher in females than in males 
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matched for age and body mass index). In this sense, leptin could be added to 
the list of hormones, such as oestradiol and prolactin, that have long been 
known to have a role in favouring the predisposition of females to the 
development of autoimmunity (103). In particular, only hyperleptinaemic 
female mice develop autoimmunity, whereas hypoleptinaemic mice are 
protected, and treatment of EAE-resistant SJL/J males with recombinant leptin 
renders them susceptible to EAE (103). 
 
Leptin in organ-specific autoimmunity of the central nervous 
system: the case of Multiple Sclerosis and EAE. 
Immunologists look at multiple sclerosis as an autoimmune disease, in which 
T-lymphocytes specific for myelin antigens start an inflammatory reaction in 
the central nervous system, which ultimately leads to demyelination and 
subsequent axonal injury. This view of multiple sclerosis as a T-cell-mediated 
autoimmune disease is derived primarily from studies on a single animal 
model, experimental autoimmune encephalomyelitis (EAE). The origins of 
EAE date back to the 1920s, when Koritschoner and Schweinburg induced 
spinal cord inflammation in rabbits by inoculation with human spinal cord. 
Since then EAE was elicited in many different species, including rodents and 
primates, and from these studies it became clear that EAE can reproduce many 
of the clinical, neuropathological and immunological aspects of multiple 
sclerosis (104).  
Multiple sclerosis (MS) is a chronic, immune-mediated, inflammatory disorder 
of the central nervous system (CNS) (105). Clinically the illness may present 
as a relapsing–remitting disease, or with steady progression of neurological 
disability. The subsequent course of disease is unpredictable, although most 
patients with a relapsing–remitting disease will eventually develop secondary 
progressive disease.  Its pathology is, in part, reflected by the formation of 
focal inflammatory demyelinating lesions in the white matter, which are the 
characteristic hallmarks in patients with acute and relapsing disease (106, 107). 
In patients with progressive disease, the brain is affected in a more global 
sense, with diffuse but widespread (mainly axonal) damage in the normal 
appearing white matter and massive demyelination also in the grey matter, in 
 21
particular in the cortex (108, 109). The mechanisms of tissue injury in focal 
white matter lesions are heterogeneous, resulting in patterns of demyelination 
that vary between patients or patient subgroups (106). The destruction patterns 
in the multiple sclerosis plaque can include a cytotoxic attack via T-cell and 
macrophages inflammation (with the secretion of perforin and granzyme as 
effector molecules directed towards the target), as well as a humoral-mediated 
destruction of the myelin sheat via local deposition of antibodies, which then 
can activate complement (fugure 4). Furthermore, there is a high inter-
individual variability in the extent of axonal damage as well as remyelination 
and repair. The reason for this complex situation is largely unknown, although 
it is likely that genetic factors influencing immune-mediated inflammation as 
well as neuronal and glial survival may play a major role in modulating the 
phenotype of the disease (106). 
 
 
Figure 4. Destruction patterns in the multiple sclerosis plaque. A) In the healthy CNS oligodendrocytes 
enheathe the axon and form myelin internodes of regular size. B) Cytotoxic attack can destry the myelin 
sheat via T-cell and macrophage inflammation. Cytotoxic T cells secrete perforin and granzyme as 
effector molecules directed towards the target (left). Humoral factors destry the myelin sheat via local 
deposition of antibodies, which then activate complement (right) or phagocytic effector cells via ADCC 
(not shown). C) Damage towards the oligodendrocyte and the axon is mediated via cytotoxic products of 
macrophages/microglia (left), with nitric oxide (NO) as one of the major constituents. Note that the 
oligodendrocyte shows typical morphology of apoptosis. On the right side, the diffuse pattern of axonal 
and myelin destruction is illustrated, where as yet no unequivocal pathogenetic mechanism has been 
identified. 
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As previously said, the most studied model of MS in animals is EAE, in which 
autoimmunity to CNS components is induced in susceptible strains of mice 
through immunization with self-antigens derived from basic myelin protein. 
The disease is characterized by autoreactive T cells that traffic to the brain and 
to the spinal cord and injure the myelin sheaths of CNS, with the result of 
chronic or relapsing-remitting paralysis (depending on the antigen and the 
strain of mice used). It has long been known that myelin-reactive Th1 CD4+ 
cells can induce and/or transfer disease, and Th1 cytokines are elevated in the 
CNS inflammatory lesions of EAE. In contrast, Th2 cytokines typically 
associate with recovery from EAE and/or protection from the disease (110). It 
has been shown that leptin is involved in both the induction and in the 
progression of EAE (110). Genetically, leptin-deficient ob/ob mice are resistant 
to induction of both active and adoptively transferred EAE. This protection is 
reversed by leptin administration and associates with a switch from Th2- to 
Th1-type responses and IgG1 to IgG2a isotype switch. Similarly, in susceptible 
wild-type C57BL/6J mice, leptin worsens disease by increasing IFN-γ release 
and IgG2a production (110). Importantly, a surge of serum leptin anticipates 
the onset of clinical manifestations of EAE (111). The peak of serum leptin 
correlates with inflammatory anorexia, weight loss, and the development of 
pathogenic T cell responses against myelin (111). Lymphomononuclear 
infiltrates in the CNS of EAE mice indicate in situ production of leptin in 
active inflammatory lesions, thus representing a significant local source of 
leptin (111) (figure 5). Systemic and/or in situ leptin secretion was instead 
lacking in EAE-resistant mice. Taken together, these data suggest an 
involvement of leptin in CNS inflammation in the EAE model of MS. In the 
human disease, it has been reported that the secretion of leptin is increased in 
both serum and cerebrospinal fluid (CSF) of naive-to-treatment patients with 
MS, an aspect that positively correlates with the secretion of IFN-γ in the CSF 
and inversely correlates with the percentage of circulating TRegs – a key subset 
of lymphocytes involved in the suppression of immune and autoimmune 
responses that is reduced in patients with MS as compared with healthy 
matched controls (112). Of note, the number of peripheral TRegs in patients with 
MS inversely correlates with the serum levels of leptin, suggesting a link 
between the number of TRegs and leptin secretion (112). Considering that TRegs 
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are generated in the thymus, it is not known whether peripheral leptin or that 
produced in the perithymic adipose tissue could affect TRegs 
generation/function in autoimmunity-prone subjects. This aspect is not defined 
yet and is object of current extensive investigation. In any case, the fact that 
increased leptin secretion occurs in acute phases of MS and correlates with 
CSF production of IFN-γ is of possible interest for the pathogenesis and 
clinical follow-up of patients with MS. As mentioned before, increased leptin 
secretion is present both in the serum and in the CSF of patients with MS and 
does not correlate with body mass index (BMI) (112). The increase of leptin in 
the CSF is higher than in the serum, suggesting possible secondary in situ 
synthesis of leptin in the CNS and/or an increased transport across the blood–
brain barrier following enhanced systemic production. A recent gene 
microarray analysis of Th1 lymphocytes from active MS lesions has shown 
elevated transcripts of many genes of the neuroimmunoendocrine axis, 
including leptin (113). Leptin transcripts were also abundant in gene 
expression profiles of human Th1 clones, confirming that leptin gene 
transcription is induced concomitantly with the polarization toward Th1 
responses – which are often involved in T-cell-mediated autoimmune diseases 
including MS. Moreover, in situ secretion of leptin near inflammatory T cells 
and macrophages was observed in active EAE lesions (110, 111). A possible 
explanation for the in situ elevated levels of leptin in the CSF of patients with 
MS could be the inflammatory cell itself, as suggested by studies with 
autoreactive human myelin basic protein (hMBP)-specific T cells from patients 
with MS that produced leptin and upregulated the expression of leptin receptor 
after activation (112). Both anti-leptin and anti-leptin receptor-blocking 
antibodies reduced the proliferative responses of the hMBP-specific T cell lines 
to antigen stimulation, underlying a possibility of leptin-based intervention on 
this autocrine loop to block autoreactivity (112). Finally, recent reports (114) 
have shown increased secretion of serum leptin before relapses in patients with 
MS during treatment with IFN-β, and a capacity of leptin to enhance in vitro 
secretion of TNF-α, IL-6, and IL-10 from peripheral blood mononuclear cells 
of patients with MS in acute phase of the disease but not in patients with stable 
disease (114). In view of all these considerations, we suggest that leptin could 
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be one of the many proinflammatory factors that act in concert to promote the 
pathogenic (autoreactive) Th1 responses targeting neuroantigens in MS. 
 
 
 
Figure 5. Lymph node and CNS expression of leptin during acute/active EAE. (A) Leptin expression in 
SJL/J female mouse adipose tissue used as positive control. (B and C) Expression of leptin in T cells and 
macrophages in a draining lymph node from SJL/J female mice after immunization with PLP139–151. 
(D) Leptin was not expressed in the brain of C57BL/6J ob/ob mice after immunization with MOG35–55 
peptide (n = 4). (E and F) Expression of leptin in inflammatory infiltrates (white square) and in choroid 
plexus (arrow) during the acute phase of EAE in C57BL/J6 WT mice (n = 4). (g) Leptin was not 
expressed in the brain of SJL/J male mice after immunization with PLP139–151 peptide (n = 6). (H and 
I). Leptin expression in inflammatory lesions in the acute phase of EAE in SJL/J female mice (n = 6). (J) 
Cerebellum of SJL/J male mice did not express leptin after immunization with PLP139–151 peptide, 
whereas in k and l leptin was expressed in inflammatory infiltrates (white square) and choroid plexus 
(arrow) of SJL/J females. (M) Spinal cord C57BL/J6 ob/ob mice immunized with MOG35–55 peptide 
did not express leptin. (N and O) Expression of leptin in neurons (white square in n) and two 
inflammatory infiltrates around blood vessels (arrows in n) detectable during the acute phase of EAE in 
C57BL/6J WT mice spinal cord. (P-R) Leptin expression was revealed in T cells present in inflammatory 
infiltrates of the brain, cerebellum, and spinal cord (arrows) of C57BL/J6 WT mice after adoptive 
transfer, but it was not detectable in the CNS of C57BL/6J ob/ob mice after adoptive transfer (not 
shown). The white squares in b, e, h, k, and n represent the zone of higher magnification shown in c, f, i, 
l, and o, respectively. 
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AIM OF THE STUDY 
 
Leptin is a cytokine-like hormone ,mainly produced by adipose tissue, that 
links nutritional status with the immune system. Data from literature suggest 
that, acting as a cytokine, leptin is able to promote proliferation and IL-2 
secretion by naive T cells, whereas on memory T cells it promotes the 
switch toward Th1 immune response, by increasing IFN-γ and TNF-α 
secretion. Moreover the pivotal role of leptin in autoimmune disease has 
been highlighted by the observation that leptin-deficient ob/ob mice are 
resistant to induction of EAE, an animal model of MS. 
We have recently reported that leptin administration to susceptible mice 
worsens EAE, by increasing secretion of pro-inflammatory cytokines. In a 
similar fashion, leptin replacement in leptin-deficient ob/ob mice restores 
susceptibility to both active and passive EAE. Since we and others have also 
described that leptin is expressed in active inflammatory lesions of the CNS 
during acute EAE and MS, the first aim of this study was to investigate the 
molecular and cellular effects induced by leptin neutralization either with 
anti-mouse leptin Abs or with soluble mouse leptin receptor chimera-Fc 
(ObR:Fc), on induction and progression of EAE (phenotypically evaluated 
in terms of changing in clinical score). More in detail, we analyzed whether 
leptin blockade could interfere with autoreactive T cells proliferation, 
cytokine profile secretion, expression of regulatory (Foxp3) and activation 
markers (ICAM-1, VLA-4, OX-40). We also evaluated the biochemical 
changes induced by leptin neutralization in the molecular machinery of 
autoreactive CD4+ T cells, analyzing a series of biochemical markers 
specific for T cell activation, anergy, and Th2/regulatory-type cytokine 
secretion. 
In the second part of this study we evaluated the possible interaction 
between leptin and regulatory T cell (CD4+CD25+Foxp3+ cells), to 
determine whether the protection from EAE onset and progression, 
mediated by leptin neutralization, could be ascribed to a direct effect of this 
treatment on regulatory T cell subset, which are known to regulate immune 
tolerance, inhibiting the autoreactive responses occuring during autoimmune 
diseases. For this purpose we analyzed leptin receptor expression on Tregs, 
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and how leptin neutralization could interfere with their state of 
hyporesponsiveness and suppressive function. Finally to better clarify and 
further characterize the phenomenon of Tregs expansion, we performed in 
vivo experiments in animal models of acute (anti-leptin treated mice) and 
chronic leptin deficiency (ob/ob mice). The full understanding of Tregs 
biology will allow us to imagine a scenario of a huge number of 
autoimmune settings where Tregs are isolated from patients either during 
remission or soon after disease onset and after their expansion, mediated by 
leptin neutralization, they could be reintroduced at the time of maximal 
disease activity to moderate the inflammatory  response. 
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RESULTS 
Leptin blockade improves clinical score and delays disease progression in 
actively induced EAE.  
We evaluated the ability of either anti-leptin neutralizing Abs or ObR:Fc 
(which is a chimeric antagonist of leptin, constituted by the extracellular 
domain of mouse leptin receptor fused to the Fc region of human IgG1) to 
affect induction and progression of EAE, after subcutaneous immunization 
with proteolipid protein 139–151 (PLP139–151) myelin peptide (day 0). 
Treatment with anti-leptin Abs, ObR:Fc or with affinity-purified IgG1 (used as 
a control) was initiated prior to immunization (from day –1 to day 1 relative to 
immunization) or during the acute phase of the disease (days 8–11), for 3 and 4 
consecutive days, respectively (Figure 5, and Table 1; see Methods for details).  
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 Figure 5. Leptin blockade during actively induced EAE with either anti-leptin Abs or ObR:Fc 
reduces the clinical severity of EAE. (A) Mean clinical score of SJL/J female mice treated with anti-
mouse leptin Abs injected either from day –1 to day 1 or on days 8–11 (100 µg/d i.p.). Data are from 1 
representative experiment of 3. (B) Mean clinical score of SJL/J female mice treated with mouse ObR:Fc 
chimera injected either from day –1 to day 1 or on days 8–11 (100 µg/d i.p.). Data are from 1 
representative experiment of 3. §P = 0.01, day –1 to day 1, #P = 0.02, day –1 to day 1, and † P = 0.04, 
days 8–11, versus PBS or control Ig. 
 
Individual mice were observed daily for clinical signs of disease for up to 40 
days. CTR-Ig treated mice developed the pathology and exhibited complete 
hind limb paralysis or fore limb weakness (score=4/4,5) after 17-20 days from 
the immunization.  While in both cases, leptin neutralization led to a 
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statistically significant reduction in EAE clinical score (about 60%), to a re-
establishment of motor functionality, as well as a decrease in the percentage of 
initial body weight loss and a reduced number of inflammatory infiltrates 
(Figure 5, and Table 1). These effects led to significant clinical improvement 
and delayed disease progression during the following 40 days of observation 
(Figure 1, A and B, and Table 1), indicating that leptin blockade inhibited both 
development and progression of EAE. Moreover, observation of animals over a 
longer period of time (90–120 days) revealed a significant reduction in relapse 
rate (Table 1), suggesting that this protection was long lasting. 
Group of 
mice 
Incidence 
No/tot (%) 
Day of 
onset 
(range) 
Peak 
clinical 
score 
No of 
Inflammatory 
foci 
Post 
treatment 
Relapse 
rate* 
PBS (Active EAE) 18/18 (100.0) 9.0 ± 0.5 (8-9) 3.6 ± 0.9 45.5 ± 10.0 2.0 
CTR-IgM 18/18 (100.0) 8.1 ± 0.5 (8-9) 3.5 ± 1.0 40.1 ± 5.0 1.94 
anti-Leptin -1 to +1 18/18 (100.0) 11.8 ± 1.0 (10-13) 2.0 ± 0.5A 15.5 ± 10A 0.55 
anti-Leptin +8 to +11 18/18 (100.0) 12. 1 ± 3.0 (8-16) 1.6 ± 0.8B 9.0 ± 4.0B 0.33 
      
PBS (Active EAE) 18/18 (100.0) 8.0 ± 0.5 (8-9) 2.7 ± 0.8 31.0 ± 10.0 1.55 
CTR-IgG1 18/18 (100.0) 8.1 ± 0.4 (8-9) 2.6 ± 0.5 31.9 ± 12.0 1.66 
ObR:Fc -1 to +1 18/18 (100.0) 9.4 ± 1.0 (8-12) 1.2 ± 0.4A 15.0 ± 7.0C 0.55 
ObR:Fc +8 to +11 17/18 (94.4) 9.0 ± 0.5 (8-10) 0.9 ± 0.5B 11.0 ± 5.0D 0.55 
      
PBS (Passive EAE) 18/18 (100.0) 7.1 ± 1.0 (6-8) 2.8 ± 1.0 27.0 ± 5.0 1.38 
CTR-IgM 18/18 (100.0) 7.0 ± 0.7 (6-8) 2.6 ± 0.8 27.5 ± 6.0 1.44 
anti-Leptin -1 to +1 18/18 (100.0) 8.8 ± 2.0 (6-11) 1.6 ± 0.8A 10.5 ± 9.0C 0.61 
anti-Leptin +8 to +11 14/18 (77.7) 17.8 ± 1.1 (17-20) 0.3 ± 0.4B 0.2 ± 0.5D 0.05 
      
PBS (Passive EAE) 18/18 (100.0) 7.2 ± 1.2 (7-8) 3.1 ± 1.0 35.5 ± 6.0 1.27 
CTR-IgG1 18/18 (100.0) 7.5 ± 0.7 (7-8) 3.0 ± 0.9 34.3 ± 10.5 1.33 
ObR:Fc -1 to +1 14/18 (77.7) 9.5 ±  0.7 (8-10) 0.5 ± 0.0B 0.5 ± 0.1D 0.0 
ObR:Fc +8 to +11 13/18 (72.2) 10.0 ± 0.7 (8-10) 0.5 ± 0.0B 0.5 ± 0.4D 0.0 
 
Table 1. Effect of treatment with either anti-leptin Abs or ObR:Fc chimera on neurological 
impairment during active and passive EAE in SJL/J female mice.  
The data shown are cumulated and averaged from three independent experiments each performed with 6 
mice/group and they are presented as mean ± SD. CTR-Ig, control immunoglobulins (see Methods for 
details of isotype controls utilized). *Post-treatment relapse rate, total number of relapses in a group 
divided by the total number of mice in that group (group of mice were observed up to 90-120 days after 
disease induction to asses the relapse rate). AP = 0.001 and BP = 0.0001 as compared with the respective 
PBS and CTR-Ig group. 
 
Leptin blockade improves clinical score and delays disease progression in    
passively induced EAE.  
We next tested the ability of either anti-leptin Abs or ObR:Fc to modify the 
onset and progression of adoptively transferred EAE. (Figure 6, A and B, and 
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Table 1). Treatment with Abs was repeated for 3–4 consecutive days, before 
(from day –1 to day 1) or after (days 8–11) the adoptive transfer of 2 × 107 
purified PLP139–151-specific CD4+ T cells (see Methods), following the same 
scheme of the experimental design descrived above . Mice treated with control 
Igs all developed severe EAE (Figure 6A and Table 1). In contrast, mice 
treated with anti-leptin Abs from day –1 to day 1 displayed a milder disease 
(Figure 6A and Table 1), while those treated on days 8–11 were fully protected 
(Figure 2A and Table 1). Treatment with ObR:Fc from day –1 to day 1 also led 
to a reduction of EAE clinical signs and delayed progression of the disease 
with significantly more efficiency than did anti-leptin Ab treatment from day –
1 to day 1 (Figure 2 B, and Table 1). A significant reduction in the relapse rate 
was also found in animals observed for 90–120 days (Table 1).  
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 Figure 6. Leptin blockade during adoptively transferred EAE with either anti-leptin Abs or 
ObR:Fc chimera reduces the clinical severity of EAE. (A) Mean clinical score of SJL/J female mice 
treated with anti-mouse leptin Abs injected either from day –1 to day 1 or on days 8–11 (100 µg/d i.p.). 
Data are from 1 representative experiment of 3. #P = 0.02, day –1 to day 1, and **P = 0.001, days 8–11, 
versus PBS or control Ig; ‡P = 0.02, day –1 to day 1 versus days 8–11. (B) Mean clinical score of SJL/J 
female mice treated with mouse ObR:Fc chimera injected either from day –1 to day 1 or on days 8–11 
(100 µg/d i.p.). Data are from 1 representative experiment of 3. **P = 0.001, day –1 to day 1 and days 8–
11 versus control Ig. 
 
Leptin blockade is accompanied by inhibition of delayed-type hypersensitivity 
and reduces autoreactive T cell proliferation to PLP139–151 peptide during 
EAE.  
To determine the nature of the in vivo T cell response against PLP139–151 
peptide in leptin-neutralized mice, delayed-type hypersensitivity (DTH) 
reactions were performed in all groups of treated mice. On day 35 of 
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observation, mice were challenged with 25 µg PLP139–151 peptide injected 
intradermally in the footpad. The degree of local footpad swelling was 
measured as readout for the DTH reaction (see Methods). Typical DTH 
kinetics were observed with footpad swelling peaking between 24–48 hours 
and subsiding after 72–96 hours. DTH responses to the PLP139–151 peptide 
priming epitope were significantly reduced in mice treated with anti-leptin Abs 
and ObR:Fc, whereas the controls exhibited a marked DTH reaction (Figure 
7A and Figure 8A). We also examined whether leptin blockade could affect 
proliferation of PLP139–151-specific T cells in vitro, measured as thymidine 
incorporation. T cell response to PLP139–151 peptide was tested on draining 
lymph nodes taken from all groups of treated mice, 15 days after immunization 
and cultured in the presence of increasing concentrations of PLP139–151. T cells 
derived from either anti-leptin Abs– or ObR:Fc-treated mice showed a 
significant reduction in proliferation (Figure 7B and Figure 8B, respectively), 
whereas no difference was observed when T cells were stimulated in parallel 
with a polyclonal stimulator such as the anti-CD3ε mAb (2C11 hybridoma, 
Figure 7C and Figure 8C, respectively; see Methods), indicating that the effect 
of leptin neutralization was restricted only to the autoreactive CD4+ T cells. Of 
note, inhibition of in vitro anti-PLP139–151 proliferation was more efficient in 
mice treated with the ObR:Fc chimera (Figure 7B and Figure 8B). 
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 Figure 7. In vivo leptin neutralization with anti-mouse leptin Abs in SJL/J mice inhibits DTH 
response and induces T cell hyporesponsiveness to PLP139–151 myelin peptide. (A) DTH reaction in 
leptin-neutralized and control Ig–treated mice measured as footpad swelling. Data are from 1 
representative experiment of 2. (B) Proliferative response of lymph node–derived T cells against 
PLP139–151. Data are from 1 representative experiment of 3. (C) Polyclonal T cell proliferation induced 
with anti-CD3ε stimulation. #P = 0.02, day –1 to day 1 and days 8–11 versus control Ig. 
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 Figure 8. In vivo leptin neutralization with mouse ObR:Fc chimera in SJL/J mice inhibits DTH 
response and induces T cell hyporesponsiveness to PLP139–151 myelin peptide. (A) DTH reaction in 
ObR:Fc leptin-neutralized and control Ig–treated mice measured as footpad swelling. Data are from 1 
representative experiment of 2. #P = 0.02, day –1 to day 1 and days 8–11 versus control Ig. (B) 
Proliferative response of lymph node–derived T cells against PLP139–151. Data are from 1 representative 
experiment of 3. **P = 0.001, day –1 to day 1, and #P = 0.02, days 8–11, versus control Ig. (C) 
Polyclonal T cell proliferation induced with anti-CD3ε stimulation. 
 
Leptin blockade in EAE is associated with a switch of the cytokine profile 
toward a Th2/regulatory phenotype and upregulation of forkhead box p3 
expression. 
 It’s well known from the literature that Th1 CD4+ Ag-specific cells are able to 
induce encephalomyelitis when adoptively transferred in normal mice and that 
cytokines secreted by Th1 cells (IFN-γ) are present in the inflammatory lesions 
of EAE in the CNS. So we next asked whether EAE protection, derived by 
leptin neutralization, was associated with an immune response characterized by 
considerable switching in the cytokine profile secretion towards a Th2 
phenotype. We checked for the presence of both pro- and anti-inflammatory 
cytokines by ELISA tests in all the different treated group of mice. The 
production of IFN-γ was significantly reduced by both leptin-neutralizing 
treatments in the presence of increasing concentrations of PLP139–151 as well as 
during polyclonal anti-CD3ε stimulation (Figure 9, A and B, and Figure 10, A 
and B). Conversely, a significant increase in the Th2/regulatory-type cytokines 
such as IL-4 (Figure 9, C and D, and Figure 10, C and D) and IL-10 (Figure 9, 
E and F, and Figure 10, E and F) was observed in the cells isolated from leptin-
neutralized mice during both anti-PLP139–151–specific proliferation and 
polyclonal stimulation with anti-CD3ε, suggesting a key role for leptin 
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blockade in the improvement of EAE, through the modulation of the cytokine 
secretion .  
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Figure 9. In vivo leptin neutralization with anti-mouse leptin Abs inhibits IFN-γ production and 
induces the secretion of IL-4 and IL-10 regulatory cytokines. IFN-γ secretion of lymph node–derived 
T cells stimulated with the myelin antigen PLP139–151 (A) and by anti-CD3ε (B). IL-4 secretion of 
lymph node–derived T cells stimulated with the myelin antigen PLP139–151 (C) and by anti-CD3ε (D). 
IL-10 secretion of lymph node–derived T cells stimulated with the myelin antigen PLP139–151 (E) and 
by anti-CD3ε (F). (A, C, and E) #P = 0.02, day –1 to day 1 and days 8–11, and **P = 0.001, days 8–11, 
versus control Ig. Data are from 1 representative experiment of 3. (B, D, and F) #P = 0.02, **P = 0.001, 
*P = 0.002, † P = 0.04 versus control Ig. 
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Figure 10. In vivo leptin neutralization with ObR:Fc inhibits IFN-γ production and induces the 
secretion of IL-4 and IL-10 regulatory cytokines. IFN-γ secretion of lymph node–derived T cells 
stimulated with the myelin antigen PLP139–151 (A) and by anti-CD3ε (B). IL-4 secretion of lymph 
node–derived T cells stimulated with the myelin antigen PLP139–151 (C) and by anti-CD3ε (D). IL-10 
secretion of lymph node–derived T cells stimulated with the myelin antigen PLP139–151 (E) and by anti-
CD3ε (F). Data are from 1 representative experiment of 3. (A) **P = 0.001, day –1 to day 1 and days 8–
11 versus control Ig. (C) **P = 0.001, day –1 to day 1, and † P = 0.04, days 8–11, versus control Ig. (E) 
**P = 0.001, days 8–11, and #P = 0.02, day –1 to day 1, versus control Ig. (B, D, and F) #P = 0.02, *P = 
0.002, † P = 0.04 versus control Ig. 
 
In addition, to determine whether treatment with ObR:Fc induced forkhead box 
p3 (Foxp3) expression, (a marker of cellular subsets with regulatory phenotype 
able to dampen the autoimmune response), in CD4+ T cells, we isolated these 
cells from mice with EAE and measured Foxp3 expression by Western blot. 
Leptin neutralization induced significant increase of Foxp3 levels (Figure 11, 
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A and B), suggesting induction of regulatory T cell markers in leptin-
neutralized mice. 
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Figure 11. Increased expression of Foxp3 in CD4+ T cells induced by leptin neutralization in mice 
with EAE. (A) Western blot analysis for Foxp3 on purified CD4+ T cells obtained from SJL/J mice 
immunized with PLP139–151 treated or not with ObR:Fc. (B) Results are presented as Foxp3 protein 
level normalized to tubulin expression. Data are from 1 representative experiment of 3. 
 
Leptin neutralization reduces the expression of ICAM-1 and OX-40 and 
upregulates very late antigen-4 on CD4+ T cells during EAE. 
 We then investigated in more detail the cellular events leading to an 
improvement of clinical symptoms and progression of EAE. Cytofluorimetric 
analysis of CD4+ T cells from mice treated with anti-leptin Abs or ObR:Fc 
obtained on day 15 after immunization with PLP139–151 revealed a significant 
reduction of ICAM-1 and OX-40 (Figure 12, A and B, respectively), both 
classically involved in the pathogenesis of EAE (115-117), suggesting that 
leptin may affect expression of key molecules on T lymphocytes, involved in 
the mechanisms of immune tolerance. Conversely, the overall expression of the 
α4β1 integrin, very late antigen-4 (VLA-4) (118), was increased, with 
particular upregulation of the population at high fluorescence intensity (Figure 
12C). The effects of leptin blockade on lymphocytes could not be ascribed to 
intrinsic toxicity of the molecule, as the circulating number and apoptosis 
(measured by annexin V staining) of CD4+, CD8+, B, γδ, NK, and monocytes 
in the spleen and lymph nodes of treated mice were not different from controls 
(data not shown). 
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Figure 12. Leptin neutralization suppresses ICAM-1 and OX-40 expression on CD4+ cells but 
upregulates VLA-4 in mice with EAE. (A) Flow cytometric analysis of cell-surface ICAM-1 molecules 
(left) and mean fluorescence intensity (MFI) from 3 independent experiments (right). (B) OX-40 surface 
expression. (C) VLA-4 expression on CD4+ T cells from ObR:Fc-treated mice and controls. #P = 0.02, 
*P = 0.002, † P = 0.04 versus control Ig.  
 
Ex vivo CD4+ T cells from leptin-neutralized mice fail to downregulate the 
anergy factor cyclin-dependent kinase inhibitor p27 and induce the ERK1/2 
and STAT6 pathways. 
 To evaluate whether leptin neutralization affects the molecular machinery of 
autoreactive CD4+ T cells, we analyzed a series of biochemical markers 
specific to T cell activation, anergy, and Th2/regulatory-type cytokine 
secretion (119-123). More specifically, we studied ex vivo purified CD4+ 
autoreactive T cells from spleens and lymph nodes of ObR:Fc-treated mice 
(both -1+1 and +8+11 treatement) on day 15 of disease, previously immunized 
with PLP139–151 peptide (see Methods). In CD4+ T cells ObR:Fc treatment led 
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to a failure to downmodulate the cyclin-dependent kinase inhibitor p27 (p27Kip-
1; Figure 13A) associated with increased tyrosine phosphorylation of ERK1/2 
(Figure 13C). Moreover, we observed an upregulation of STAT6 tyrosine 
phosphorylation levels (Y641, known to be associated with Th2/regulatory-
type cytokine secretion; (123) in ObR:Fc-treated mice compared with control 
mice (Figure 13E). Taken together, these data underline the capability of leptin 
neutralization in modulating functionality of pro-pathogenic T cells, by altering 
their proliferative/anergy rate and inducing the expression of molecules with 
regulatory functions. 
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Figure 13. Leptin neutralization determines the failure to downmodulate the anergy factor p27Kip-
1 and is associated with sustained phosphorylation of ERK1/2 and STAT6. (A and B) Western blot 
analysis for p27Kip-1 and tubulin on purified CD4+ T cells obtained from naive (C and D) Western blot 
analysis for phosphorylation of ERK1/2 in resting CD4+ T cells from naive and SJL/J mice immunized 
with PLP139–151, treated or not with ObR:Fc. (E and F) Western blot analysis for phosphorylation of 
STAT6 in resting CD4+ T cells from naive and SJL/J mice immunized with PLP139–151, treated or not 
with ObR:Fc. For each panel, 1 representative experiment of 5 is shown. 
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Human Treg cells express higher level of Leptin receptor (ObR) than do 
CD4+CD25− effector T cells. 
To evaluate whether clinical improvement of EAE, induced by leptin 
neutralization, could be ascribed to the effect of this kind of treatment on the 
homeostasis and function of regulatory T cells (a specific cellular subset, 
known to control the mechanisms of immune tolerance), we performed a series 
of experiments to check and confirm a possible link between leptin and/or its 
neutralization and Tregs. Previous studies have shown that leptin receptor 
(ObR) is expressed on CD4+ T cells and that it is able to switch immune 
responses toward a T helper 1 (Th1) phenotype (124). We sought to analyze 
the expression of ObR also on Treg cells and to correlate its expression with 
Foxp3, to check whether leptin could act directly on Tregs subpopulation. First 
of all CD4+CD25+ Treg cells and CD4+CD25− effector T cells purified from 
human healthy donors (Figure 14A, left) were analyzed for Foxp3 expression 
by FACS analysis and immunoblot (Figure 14A, right, and Figure 14B, 
respectively), to confirm the purity of our preparation. As expected, Treg cells 
showed high amounts of Foxp3 protein whereas CD4+CD25− did not show 
detectable amount of the protein in cell extracts (Figures 14A and 14B). 
Instead, ObR was expressed on both freshly isolated cellular subsets, although 
at significantly higher amounts (p < 0.001) in Treg cells as compared to the 
CD4+CD25− T cell effectors (Figure 14C). 
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Figure 14. Human Treg Cells Express High ObR, and (A) Representative flow cytometry plot of 
human T cells stained for CD4, CD25, and Foxp3. (B and C) Immunoblot analysis of sorted CD4+ T 
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cells on the basis of their CD25 expression. Graphs show quantitation of Foxp3 and ObR with respect to 
tubulin. One representative out of five independent experiments is shown. 
 
Leptin neutralization induces proliferation of human Treg cells upon anti-
CD3 and anti-CD28 stimulation. 
Human Treg cells were hyporesponsive to anti-CD3 and anti-CD28 stimulation 
(Figure 15A), in agreement with previous findings from the literature (125). 
Addition of exogenous recombinant leptin to the cultures did not alter Treg cells 
hyporesponsiveness (Figure 15A). However, addition of neutralizing leptin 
monoclonal antibody (mAb) reversed their state of hyporesponsiveness and 
promoted Treg cell proliferation (Figure 15A), in a dose-dependent fashion 
(Figure 15B). Confirming specificity, addition of exogenous recombinant 
leptin to anti-CD3- and anti-CD28-stimulated Treg cells antagonized the 
proliferation induced by leptin mAb (Figure 15A). Moreover, dose-dependent 
increase of the proliferation of stimulated Treg cells in the presence of leptin 
mAb (Figure 15B) was reversed by addition of increasing doses of 
recombinant leptin (Figure 15C). Conversely, leptin mAb inhibited the 
proliferation of purified effector CD4+CD25− T cells, a phenomenon that was 
reversed by addition of exogenous leptin (Figure 15D). Thus, neutralization of 
leptin had opposite effects on effector CD4+CD25− T cells and Treg cells—it 
inhibited proliferation on the former lymphocyte subset (Figure 15D), whereas 
it promoted expansion of the latter subpopulation (Figure 15A). This effect was 
also evident morphologically, as formation of cell clumps in the cultures of Treg 
cells stimulated with anti-CD3 and anti-CD28 and leptin mAb, but not in the 
cultures of Treg cells stimulated with anti-CD3 and anti-CD28 in the absence of 
leptin mAb (data not shown). Finally, in coculture experiments, Treg cells 
efficiently suppressed the proliferation of CD4+CD25− T cells, and leptin 
neutralization reversed the suppression by Treg cells (Figure 15E). 
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Figure 15. Leptin neutralization reverses Tregs hyporesponsiveness. (A) Proliferation of 
CD4+CD25+ Treg cells treated with recombinant human leptin (250 ng/ml) in the presence or absence of 
leptin mAb (10 μg/ml). The data are shown as mean ± SD (n = 5, *p < 0.0001; **p < 0.01). (B) Dose 
dependency of Treg cell proliferation induced by leptin mAb. Proliferation was measured after treatment 
with indicated doses of leptin mAb. The data are shown as mean ± SD (n = 5). (C) Proliferation of Treg 
cells induced by a fixed dose of leptin mAb in the presence of increasing concentration of recombinant 
leptin. The data are shown as mean ± SD (n = 5). (D) Proliferation of CD4+CD25- effector T cells treated 
with recombinant human leptin (250 ng/ml) in the presence or absence of leptin mAb (10 μg/ml). The 
data are shown as mean ± SD (n = 5, *p < 0.01; **p < 0.01). (E) Proliferation of CD4+CD25- effector T 
cells, Treg cells, and of both cell types in coculture in the presence or absence of leptin mAb (10 μg/ml). 
The data are shown as mean ± SD (n = 5, *p < 0.01; **p < 0.0001). 
 
Anti-leptin-expanded Treg cells have partial suppressive capacity that attains 
full activity when they enter the resting phase 
The suppressive capability of Treg cells in the presence of leptin mAb was 
tested in coculture experiments of Treg cells together with CD4+CD25− T cells. 
Addition of exogenous leptin did not affect suppression of Treg cells on 
CD4+CD25− T cells (Figure 16A). In contrast, suppression of proliferation was 
apparently abrogated in the presence of leptin mAb (Figure 16A, gray 
columns). Concomitant addition of leptin together with the leptin mAb partly 
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reduced the anti-leptin-induced reversal of suppression, confirming specificity 
for leptin neutralization in the coculture experiments (Figure 16A, gray 
columns). To understand whether Treg cells during anti-leptin-induced 
proliferation could exert suppressive capacity, since it seemed from the amount 
of incorporated thymidine in the coculture experiments, that they apparently 
lost this function, we performed coculture experiments with CFSE-labeled 
CD4+CD25− T cells in the presence of unlabeled Treg cells (Figures 16B–16E). 
As expected, Treg cells suppressed the expansion of CD4+CD25− effectors 
(Figure 16D), and suppression was partially maintained in the presence of 
leptin mAb (Figure 16E)—albeit at a lower degree when compared with 
untreated Treg cells (Figure 16D). This suggested that Treg cells during anti-
leptin-induced proliferation are partially functional in terms of suppressive 
capability. Moreover, the coculture experiments of Treg cells with CD4+CD25− 
T cells, in the presence of leptin mAb, indicated that the reversal of 
suppression (Figure 16A, gray columns) was apparent only because 
CD4+CD25− effectors were inhibited in part in their proliferation, as indicated 
by the CFSE dilution (Figure 16E). Thus, the high amount of [3H]thymidine 
incorporation in coculture of Treg cells with CD4+CD25− T cells in the presence 
of leptin mAb (Figures 15E and 16A) has to be ascribed mainly to Treg cell 
proliferation and partly to CD4+CD25− T cells. In parallel these phenomena 
were confirmed in terms of expression of the activation marker CD25 on 
CFSE-labeled CD4+CD25− effector T cells. The anti-CD3 and anti-CD28 
activation induced a substantial upregulation of CD25 on the cell surface 
(Figure 16F) and was significantly inhibited in the presence of Treg cells 
(Figure 16H). A significant reduction of CD25 expression on effector T cells 
was observed in the presence of anti-leptin-expanding Treg cells (even if at 
lower extent when compared with untreated Treg cells) (Figure 16I). In any 
case, the suppressive capacity of anti-leptin-expanding Treg cells was 
diminished by about 40%, and a certain number of CD4+CD25− T cells was 
still able to proliferate and divide (Figure 16E). 
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Figure 16. Human Treg cells exhibit partial suppressive capacity upon leptin-mAb-induced 
Proliferation. (A) Proliferation of CD4+CD25- effector T cells, Treg cells, and of both cell types in 
coculture treated with recombinant human leptin (250 ng/ml) in the presence or absence of leptin mAb 
(10 μg/ml). The data are shown as mean ± SD (n = 3, *p < 0.0001; **p < 0.01). (B–I) Proliferative 
response (B–E) and CD25 expression analysis (F–I) of CFSE-labeled-CD4+CD25- effector T cells alone 
or in coculture with untreated or leptin-mAb-treated unlabeled Treg cells. The thin line represents the 
isotype-matched negative control and the thick line represents the CD25 staining. One representative out 
of three independent experiments is shown (*p < 0.0001; **p < 0.01; ***p < 0.05, as compared with 
CD4+CD25-CFSE+). 
 
Leptin production from human Treg cells 
Leptin is present in media supplemented with human serum, such as the 
medium used in our experimental procedures. To test whether human Treg cells 
could expand in the absence of leptin, we stimulated Treg cells with anti-CD3 
and anti-CD28 in three different types of serum- and leptin-free media 
(Figure 17A), RPMI, HyQ-ADCF and X-VIVO. Under these conditions, Treg 
cells maintained hyporesponsiveness even in the absence of exogenous leptin. 
Surprisingly, addition of leptin mAb to the cultures resulted in Treg cell 
expansion (Figure 17A). This finding was also confirmed by BrdU 
incorporation in serum-free medium cultures (Figure 17B), where it’s shown 
that leptin neutralization was able to increase the percentage of BrdU positive 
cells from 2.5 to 40 in Tregs subset. This finding suggests the possibility that 
leptin may be produced directly by Treg cells in a fashion really similar to the 
production of leptin by CD4+ T cells and monocytes in multiple sclerosis (111, 
112). To test this possibility, we examined leptin and ObR expression on Treg 
cells and CD4+CD25− T cells, by confocal microscopy. Both freshly isolated 
Treg cells and CD4+CD25− T cells stained positive for leptin and ObR, with 
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different intensity patterns (Figure 17C). Moreover, after 1 hr culture, Treg cells 
showed higher leptin production than did CD4+CD25− T cells, and this 
tendency was maintained during anti-CD3 and anti-CD28 stimulation, both in 
the presence and in the absence of leptin mAb (Figure 17C). Parallel 
quantitation by immunoblotting analysis for leptin on cell lysates confirmed the 
difference (Figure 17D). Indeed, the presence of a basal production of leptin 
increased significantly after anti-CD3 and anti-CD28 stimulation (Figure 17D), 
and Treg cells always produced more leptin than did CD4+CD25− T cells 
(Figure 17D). Interestingly, leptin neutralization induced a compensatory leptin 
production and ObR upregulation in both Treg cells and CD4+CD25− T cells, 
and again, to a higher amount in the Treg cells (Figures 17C and 17D). These 
results were confirmed at 12 hr by confocal microscopy and immunoblotting 
studies (data not shown).  
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Figure 17. Treg cells produce leptin and express high amounts of ObR. (A) Proliferation of 
CD4+CD25- effector T cells, Treg cells, and of both cell types in coculture in three different serum- and 
leptin-free media in the presence or absence of leptin mAb. The data are shown as mean ± SD (n = 6, *p 
< 0.01; **p < 0.001). (B) Flow cytometry plot of BrdU incorporation of CD4+CD25- effector T cells, 
Treg cells, and of both cell types in coculture in serum-free medium (X-VIVO), in the presence or 
absence of leptin mAb during anti-CD3 and anti-CD28 stimulation. One representative out of three 
independent experiments is shown (*p < 0.05; **p < 0.001). (C) Confocal microscopy of freshly isolated 
and 1 hr-stimulated Treg cells and CD4+CD25- effectors stained for leptin (in green) and leptin receptor 
(ObR) (in red). One representative out of three independent experiments is shown. (D) Immunoblot for 
leptin on cell lysates from Treg cells and CD4+CD25- effectors. The graph shows quantitation of leptin 
with respect to total ERK1/2. One representative out of three independent experiments is shown.  
 
Additionally, to address the capacity of Treg cells and CD4+CD25− T cells to 
secrete leptin, we performed a human leptin-specific ELISA at different time 
points (12 hr and 36 hr) on culture supernatants (Figure 18). At 12 hr, the 
secretion of leptin was similar in both Treg cells and CD4+CD25− T cells, 
whereas at 36 hr the amount of leptin secreted was significantly higher in the 
Treg cells, either unstimulated or treated with anti-CD3 and anti-CD28 plus 
leptin mAb (Figure 18). Finally, these results on leptin secretion were also 
confirmed by immunoblotting for leptin on culture supernatants (data not 
shown). Thus, these results suggest the presence of an autocrine loop of leptin 
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secretion by Treg cells controlling their hyporesponsiveness and acting as a 
negative signal, constraining Tregs expansion. 
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Figure 18. Tregs cells secrete leptin in the culture supernatant. Human leptin specific ELISA 
performed on cell culture media at 12h and 36h after stimulation.   
 
Leptin neutralization increases the expression of Foxp3 in Treg cells  
We next addressed whether leptin neutralization could affect the amount of 
Foxp3 in Treg cells. Foxp3 expression was evaluated after leptin neutralization 
at 1 hr (early time point) and 12 hr (late time point) during anti-CD3 and anti-
CD28 stimulation. As shown in Figure 19A, Foxp3 expression was increased at 
early time points after anti-CD3 and anti-CD28 stimulation, and leptin mAb 
treatment did not alter Foxp3 protein amounts. Conversely, at 12 hr, Treg , 
whose expansion is mediated by leptin blockade, showed increased Foxp3 
amounts when compared to those simply activated with anti-CD3 and anti-
CD28 alone (Figure 19B). As expected, Foxp3 was undetectable in 
CD4+CD25− T effectors after 1 hr of stimulation in all the experimental 
conditions (Figure 19A), whereas at 12 hr, there was a little expression of 
Foxp3 after anti-CD3 and anti-CD28 stimulation either in the presence or in the 
absence of leptin mAb that did not reach statistical significance (Figure 19B). 
All these data were confirmed by FACS analysis and real-time PCR.  
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Figure 19. Leptin neutralization increases the expression of Foxp3 in Treg (A) Immunoblot analysis of 
CD4+CD25- effector T cells and Treg cells in the presence or absence of leptin mAb, at 1 hr stimulation 
with anti-CD3 and anti-CD28. The graph shows quantitation of Foxp3 with respect to tubulin. One 
representative out of five independent experiments is shown. (B) Immunoblot analysis and flow 
cytometry plot of CD4+CD25- effector T cells and Treg cells in the presence or absence of leptin mAb, at 
12 hr stimulation with anti-CD3 and anti-CD28. The graph shows quantitation of Foxp3 with respect to 
tubulin. One representative out of five independent experiments is shown (*p < 0.01, as compared with 
anti-CD3 and anti-CD28). 
 
Leptin deficiency promotes Treg cells proliferation in mice 
Treg cells, despite their in vitro hyporesponsiveness, can expand in vivo in 
normal, nonlymphopenic hosts (126, 127). We used nonirradiated, 
nonlymphopenic recipient mice to avoid a homeostatic expansion of the Treg 
cells that would occur in lymphopenic hosts. The in vivo proliferative capacity 
of Treg cells in anti-leptin-treated wild-type (WT) mice versus control-Ig-
treated mice was tested with CFSE-labeled-CD4+ T cells from normal WT 
mice and by measuring the CFSE dilution in the CD4+Foxp3+ cells 
(Figure 20A). Mouse Treg cells expanded in vivo more robustly and earlier (day 
4 and day 7 after transfer) when adoptively transferred into leptin-neutralized 
WT mice (Figure 20A). This result was confirmed by adoptive transfer of 
CFSE-labeled-CD4+ T cells from normal WT mice into leptin-deficient ob/ob 
mice, in which the Treg cells, because of the absence of leptin, expanded more 
robustly and earlier (day 4 and day 7 after transfer) when compared with cells 
transferred into normal WT mice (Figure 20B). To avoid interference of CD4+ 
T cell lymphopenia on the Treg cell expansion in vivo, in the adoptive transfer 
experiments in ob/ob mice, we utilized 6-week-old mice (in which the leptin 
deficiency has not yet determined significant reduction of the CD4+ T cell 
number). We confirmed these results by looking at the modulation of Foxp3 
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expression, by western blot, in all the  differently treated mice, and we showed  
that Treg cells from the leptin-neutralized WT mice exhibited higher amount of 
this key molecule (Figure 20C).  
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Figure 20. In vivo leptin neutralization or congenital leptin deficiency associate with proliferation of 
Treg cells. (A) Proliferation measured as CFSE dilution of CFSE-labeled Treg cells obtained from WT 
mice and transferred into control (CTR)-Ig or mouse leptin neutralizing Ab-treated WT mice. The 
histogram shows the percent of CFSE+ Treg cells (gated on CD4+Foxp3+ cells) that had divided 4 and 7 
days after transfer. One representative out of three independent experiments with 3 mice per group is 
shown (*p < 0.01; **p < 0.001). (B) CFSE dilution profile of CFSE-labeled Treg cells (gated on 
CD4+Foxp3+ cells) obtained from WT mice and transferred into WT or leptin-deficient ob/ob mice, 4 
and 7 days after transfer. One representative out of three independent experiments with 3 mice per group 
is shown (*p < 0.01; **p < 0.001). (C) Ex vivo immunoblot and protein quantification of Foxp3 protein 
in Tregs cell from CTR-Ig and Leptin-Ab-trated WT mice. One representative out of three indipendent 
experiments with 3 mice per group is shown. 
 
Leptin-deficient mice have increased numbers of Treg cells that can be 
reduced by administration of leptin 
Mice with genetic deficiency of leptin (ob/ob) or leptin-receptor (db/db) have 
reduced susceptibility to autoimmunity (91, 110, 111). Treg cells play a central 
role in regulating autoimmune responses (128, 129). So we tested whether 
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protection from autoimmune attacks observed in genetic deficiency of leptin, 
could be associated with altered Treg cells expansion. A significant increase of 
the percentage of peripheral Treg (expressed as CD4+CD25+ cells(A) or 
CD4+Foxp3+ cells(B)) cells was observed in ob/ob as compared to WT 
(Figures 21A and 21B, respectively). Administration of leptin reduced the 
elevated number of Treg cells in the ob/ob mice to a number comparable to that 
found in the WT mice (Figures 21A and 21B), confirming the negative role 
played by leptin in the control of Treg cells homeostasis and function. 
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Figure 21. Effect of congenital leptin deficiency on the number of Treg ells in vivo (A) Percentage 
numbers of peripheral CD4+CD25+ Treg cells in WT, leptin deficient ob/ob mice, and recombinant 
leptin-treated ob/ob mice. One representative out of three independent experiments with 8 mice per group 
is shown (*P < 0.02). (B) Percentage numbers of peripheral CD4+Foxp3+ Treg cells in WT and leptin 
deficient ob/ob mice. One representative out of three independent experiments with 7 mice per group is 
shown (**P < 0.02). 
 
Proliferative potential and functional capacity of Treg cells from leptin 
receptor-deficient mice. 
We studied the in vitro proliferation and suppressive capacity of CD4+CD25− 
effectors and Treg cells from congenitally leptin-receptor-deficient db/db mice 
and normal db/+ heterozygous controls (Figures 22A–22C). Stimulation with 
anti-CD3 and anti-CD28 of CD4+CD25− effector T cells from db/db mice was 
less effective in inducing proliferation than stimulation on CD4+CD25− from 
db/+ mice (Figure 22A). Conversely, in vitro stimulation of Treg cells from 
db/db mice induced significantly higher proliferation than that of Treg cells 
from db/+ heterozygous controls (Figure 22B). These data suggested that the 
absence of the ObR impaired the expansion of CD4+CD25− effectors and 
enhanced the proliferative potential of Treg cells. The ObR deficiency seemed 
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to affect the proliferative potential of the Treg cells rather than their qualitative 
or functional activity, because Treg cells from db/db mice suppressed the 
proliferation of CD4+CD25− T cells in a fashion similar to that of Treg cells 
from db/+ control mice (Figure 22C), confirming the finding that addition of 
exogenous leptin did not alter the suppressive capacity of Treg cells in vitro. 
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Figure 22. ObR deficiency increases Treg cells proliferative potential, does not alter their 
suppressive capacity, and impairs CD4+CD25- proliferation.  (A) Proliferation of CD4+CD25- 
effector T cells from db/+ and leptin receptor-deficient db/db mice stimulated with anti-CD3 and anti-
CD28. The data are shown as mean ± SD (n = 5, *p < 0.001). (B) Proliferation of Treg cells from db/+ 
and db/db mice stimulated with anti-CD3 and anti-CD28. The data are shown as mean ± SD (n= 5, **p < 
0.01).  (C) Proliferation of CD4+CD25- effector T cells from db/+ mice in the presence of increasing 
number of either db/+ or db/db Treg cells, stimulated with anti-CD3 and anti-CD28. The data are shown 
as mean ± SD (n = 5). 
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MATERIAL AND METHODS 
 
Mice. Female SJL/J mice (H-2s), 6–8 weeks old, were obtained from 
Harlan-Italy. 6-week-old female leptin-deficient C57BL6/J-ob/ob (ob/ob), 
C57BL6/J, leptin-receptor deficient C57BL/Ks-db/db (db/db), and 
C57BL/Ks-db/+ lean controls (db/+) mice were purchased from Harlan 
Italy s.r.l. (Corezzana, Italy); All animal experiments were approved by the 
Istituto Superiore di Sanità (Rome, Italy). All mice were age matched for 
individual experiments and were group housed (2–6 mice per standard cage 
according to the different experimental protocol) with a 12-hour light/dark 
cycle. Paralyzed mice were afforded easier access to food and water to 
prevent dehydration. 
Reagents and Abs. We used the immunodominant mouse PLP139–151 peptide 
(HSLGKWLGHPDKF) in this study. It was synthesized by INBIOS s.r.l.; 
purity was assessed by HPLC (>97% pure), and amino acid composition 
was verified by mass spectrometry. PLP139–151 peptide batches for in vivo 
and in vitro assays were all from 1 preparation initially solubilized in LPS-
free saline solution at 4 mg/ml concentration and stored at –80°C. ObR:Fc 
was from R&D Systems. It is constituted by the extracellular domain of 
mouse leptin receptor (ObR) fused to the Fc region of human IgG1. The 
endotoxin level for all experimental Abs was ≤0.1 ng/µg protein. The mouse 
anti-leptin polyclonal Ab was produced in our laboratory after immunization 
of C57BL/6J mice with mouse recombinant leptin (R&D Systems) 
emulsified in CFA (Difco; BD Diagnostics — Diagnostic Systems); anti-
mouse leptin-specific Abs (of the IgM class) were affinity purified from 
serum and ascites of immunized mice, with recombinant mouse leptin 
bound to AminoLink Plus Immobilization Gel (AminoLink Plus 
Immobilization kit; Pierce Biotechnology Inc.). For treatment with anti-
leptin Abs, affinity-purified IgM was used as a control (BD Biosciences — 
Pharmingen); for ObR:Fc fusion protein treatment, affinity-purified IgG1 
was used as a control (BD Biosciences — Pharmingen). For in vitro 
blocking experiments, human leptin-neutralizing mAb (R&D Systems, 
Minneapolis, MN) was used at a final concentration of 0.25 to 25 µg/ml; 
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controls were irrelevant isotype-matched antibodies (Biovendor Laboratory 
Medicine Inc., Brno, Czech Republic). Human recombinant leptin was 
purchased from R&D Systems. FITC-anti-human-CD4 and PE-anti-human-
CD25 were from BD Pharmingen; the anti-human Foxp3 staining set was 
from eBiosciences (San Diego, CA)..  
EAE induction and clinical and histological assessment. For active 
induction of EAE, mice (n = 6 per group) were immunized s.c. in the flank 
with 100 µl CFA (Difco; BD Diagnostics — Diagnostic Systems) 
emulsified with 100 µg PLP139–151 peptide on day 0 and with 200 ng 
pertussis toxin (Sigma-Aldrich s.r.l.) i.p. on days 0 and 1. Control mice (n = 
5 per group) were injected with CFA emulsified with PBS plus pertussis 
toxin according to the same schedule (data not shown). For adoptively 
transferred EAE, 9–10 female donor SJL/J mice (6–8 weeks old) were 
primed s.c. with 200 µg PLP139–151 peptide in CFA distributed over 4 sites. 
After 9–10 days, draining lymph nodes (axillary and inguinal) and spleens 
were harvested, homogenized into single-cell suspension, and cultured 
separately in vitro in 24-well plates (8 × 106 cells/well, Falcon; BD) in the 
presence of 25 µg/ml PLP139–151 peptide. After 4 days in culture, 
nonadherent cells were harvested and centrifuged over Ficoll gradient 
(Pharmacia), and CD4+ T cells were purified by passing the cells over the 
CD4+ subset columns (R&D Systems). Recipient syngeneic naive female 
SJL/J mice received, in a 200-µl PBS i.v. injection, 2 × 107 highly purified 
PLP139–151-specific CD4+ T cells. Mice also received 200 ng pertussis toxin 
immediately after cell transfer as well as 1 day later. Individual mice were 
observed daily for clinical signs of disease for up to 40 days after 
immunization and after adoptive transfer. Mice were weighed and scored 
daily in a blinded fashion according to clinical severity of symptoms on a 
scale of 0 to 6, with 0.5 points for intermediate clinical findings: grade 0, no 
abnormality; grade 0.5, partial loss of tail tonicity, assessed by inability to 
curl the distal end of the tail; grade 1, reduced tail tone or slightly clumsy 
gait; grade 2, tail atony, moderately clumsy gait, impaired righting ability, 
or any combination; grade 3, hind limb weakness or partial paralysis; grade 
4, complete hind limb paralysis or fore limb weakness; grade 5, tetraplegia 
or moribund state; grade 6, death. The data were plotted as daily mean 
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clinical score for all animals in a particular treatment group. Scores of 
asymptomatic mice (i.e., scores of 0) were included in the calculation of the 
daily mean clinical score for each group. A relapse was defined as a 
sustained (more than 2 days) increase in clinical score by at least 1 full 
grade after the animal had improved previously by at least 1 full grade and 
stabilized for at least 2 days. The data are plotted as the relapse rate of all 
the animals of that group (total number of relapses per group divided by 
total number of mice in the group; see Table 1). The brains and spinal cords 
were dissected between 15 and 20 days after immunization, according to the 
clinical stage of disease, and fixed in 10% formalin. Paraffin-embedded 
sections of 5 µm thickness were cut and stained with H&E (Sigma-Aldrich). 
Sections from 4–10 segments per mouse were examined blindly for the 
number of inflammatory foci by using a previously published scoring 
system. 
In vivo Ab treatment. For EAE experiments, Mice were treated 3 or 4 times 
with 100 µg control mouse IgM or control mouse IgG1 or with anti-mouse 
leptin-specific blockers (either anti-leptin Abs or ObR:Fc chimera, 
respectively) i.p. in a total volume of 100 µl of PBS. Treatment was initiated 
with PLP139–151 peptide or the adoptive transfer of pathogenic T cells for 3 
consecutive days (days –1, 0, and 1) or during the acute phase of the disease 
for 4 consecutive days (days 8–11). ob/ob mice were injected 
intraperitoneally twice daily for 10 days with mouse recombinant leptin 
(R&D Systems) dissolved in 200 µl of PBS at a dose of 1 µg/g of body 
weight. In adoptive transfer experiments, WT mice were treated for 3 days 
either with 100 µg of control mouse IgM or with mouse leptin Abs 
intraperitoneally in a total volume of 100 µl of PBS. 
Induction of DTH (footpad-swelling assay). DTH responses to PLP139–151 
peptide during induction of disease were also quantitated using a time-
dependent (12–72 hours) footpad-swelling assay. Briefly, mice previously 
sensitized with PLP139–151 in CFA were challenged by s.c. injection of 25 µg 
PLP139–151 (in 50 µl PBS) into the right hind footpad. PBS alone was 
injected into the left footpad to serve as a control for measurements. As a 
negative control, we used mice sensitized with CFA alone. Footpad 
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thickness was measured 12, 24, 48, and 72 hours after challenge by an 
experimenter blinded to sample identity using a caliper-type engineer’s 
micrometer. The footpad swelling response was calculated as the thickness 
of the right footpad (receiving antigen) minus the baseline thickness of the 
left footpad (receiving PBS). 
Adoptive transfer experiments were performed by labeling highly purified 
(98% pure by FACS analysis) CD4+ T cells obtained from C57BL6/J WT 
mice (cells were purified with the mouse CD4+ negative isolation kit from 
Dynal) with the fluorescent dye CFSE (5-, 6-carboxyfluorescein diacetate 
succinimidyl ester) from Molecular Probes (Eugene, OR) used at 1 µg/ml. 
In brief, 107 CFSE-labeled CD4+ T cells were adoptively transferred into 
mice intravenously. 4 and 7 days later, spleen cells were harvested from 
mice and stained with PE-anti-Foxp3 (eBioscience) and Cy-anti-CD4 (BD 
PharMingen). Flow cytometric analysis of CFSE dilution was performed by 
gating on CFSE+CD4+Foxp3+ cells with a FACScalibur (Becton-Dickinson, 
San Diego, CA) and analyzed by Cell Quest software (Becton-Dickinson.) 
Proliferation assays and cytokine analysis (ELISA). Spleen and lymph 
node cells were obtained from mice 15 days after PLP139–151 sensitization, 
dissociated into single-cell suspension, and cultured for proliferation assays 
in flat-bottomed, 96-well microtiter plates (Falcon; BD) at a density of 5 × 
105 viable cells per well in a total volume of 200 µl RPMI-1640 medium 
(Invitrogen Corp.) supplemented with 2% FCS (Invitrogen Corp.), 2 mM L-
glutamine (Invitrogen Corp.), 0.1 mM nonessential amino acids (Invitrogen 
Corp.), 1 mM sodium pyruvate (Invitrogen Corp.), 50 µM 2-
mercaptoethanol (Sigma-Aldrich), and 100 U/ml penicillin and 100 µg/ml 
streptomycin (Invitrogen Corp.). Cells were cultured at 37°C in 100% 
humidity and 5% CO2 in the presence or absence of varying concentrations 
of PLP139–151 peptide (0–50 µg/ml). As a control for proliferation, anti-CD3 
Ab stimulation (2C11, 0.5 µg/ml final concentration; BD Biosciences – 
Pharmingen) was also performed. After 48–60 hours’ culture, cell 
supernatants (100 µl) were removed from single wells and frozen at –80°C 
for cytokine assay. IFN-γ, IL-4, and IL-10 were measured by ELISA 
developed in our laboratory using cytokine-specific capture and detection 
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Abs (Abs R4-6A2 and XMG1.2 for detection of IFN-γ; Abs BVD4-1D11 
and BVD6-24G2 for the detection of IL-4; and Abs JES5-2A5 and SXC-1 
for the detection of IL-10) according to the manufacturer’s instructions (BD 
Biosciences — Pharmingen). Standard curves for each assay were generated 
using recombinant mouse cytokines (IFN-γ, IL-4, and IL-10; BD 
Biosciences — Pharmingen), and the concentration of the cytokines in the 
cell supernatants was determined by extrapolation from the appropriate 
standard curve. The lower limits of detection for each assay were 2 pg/ml 
for IFN-γ, 0.6 pg/ml for IL-4, and 3 pg/ml for IL-10. The remaining cells 
were incubated for an additional 16 hours, pulsed with 0.5 µCi/well of [3H] 
thymidine (Amersham Pharmacia Biotech), harvested on glass-fiber filters 
using a Tomtec (Orange) 96-well cell harvester, and counted in a 1205 
Betaplate liquid scintillation counter (Wallac). Results obtained from 
triplicate cultures are expressed as mean cpm ± SD. Human leptin-specific 
ELISA was purchased from R&D Systems and measurements were 
performed according to the manufacturer's instructions. Serum-free media 
were RPMI (Life Technologies), HyQ-ADCF (Animal Derived Component 
Free, from Hyclone-Pierce), and X-VIVO (BioWittaker). 
Purification and culture of Tregs.. Human CD4+CD25+ and CD4+CD25− T 
cells were purified from human healthy donors PBL either by magnetic cell 
separation with the Dynal CD4+CD25+ Treg Kit (Dynal-Biotech, Oslo, 
Norway) or by flow cytometry cell sorting (MoFlo high-performance cell 
sorter, Dako, Glostrup, Denmark) and were rapidly cleaned with the Detach 
reagent (Dynal-Biotech) from surface-bound CD25 mAb. Both magnetic 
beads-based and flow cytometry-based purification techniques yielded a 
highly expressing CD25+ population (95%–98% pure by FACS analysis), 
90% of which expressed Foxp3. The Treg cells:effector ratio in the 
suppression experiments was 1:1. Cells were cultured (5 × 104 cells/well) in 
round-bottom 96-well plates (Becton-Dikinson Falcon, Franklin Lakes, NJ) 
with RPMI medium supplemented with 2 mM L-glutamine, 100 U/ml 
penicillin, 100 µg/ml streptomycin (all from Life Technologies Inc., 
Gaithersburg, MD) and 5% AB human serum (Sigma-Aldrich, St. Louis, 
MO). Cells were stimulated for 3 days in the presence of anti-CD3/CD28 
Dynabeads (0.1 bead/cell) (Dynal-Biotech). On the last day, [3H]thymidine 
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(0.5 µCi/well) (Amersham-Pharmacia Biotech, Cologno Monzese, Italy) 
was added to the cultures and cells harvested after 12 hr. Radioactivity was 
measured with a β-cell-plate scintillation counter (Wallac, Gaithersburg, 
MD). For suppression experiments in the mouse, Treg cells were isolated 
with the Regulatory T Cell Isolation Kit (Miltenyi Biotec, Gladbach, 
Germany) and stimulated with Dynabeads mouse anti-CD3/CD28 (0.5 
bead/cell; 5 × 104 cells/well). The Treg cells:effector ratio in the suppression 
experiments was 1:2. Purified cells (98% pure by FACS analysis) were 
cultured in round-bottom 96-well plates (Becton-Dikinson Falcon) with 
RPMI medium supplemented with 2 mM L-glutamine, 100 U/ml penicillin, 
100 µg/ml streptomycin (Life Technologies) and 5% FCS or 5% mouse 
serum (Hyclone-Pierce, Rockford, IL). Cells were stimulated for 3 days, 
labeled with [3H]thymidine (0.5 µCi/well) for the last 16 hr of culture, and 
harvested similarly to what done for human T cell cultures. 
Incorporation of Bromodeoxyuridine (BrdU) and FACS analysis were 
performed in T cell cultures in serum-free medium (X-VIVO) with the 
BrdU Flow Kit from BD-Pharmingen in accordance to the manufacturer's 
instructions. Briefly, isolated tregs and effector t cells were labelled in vitro 
with BrdU (10µM final concentration), then, after 48 hours we performed 
an immunofluorescent staining of cell surface antigens (CD4, CD25). After 
fixation and permeabilization process (with BD Cytofix/Cytoperm buffer) 
the cells were treated with DNase (30µg of DNase for 106 cells) to expose 
BrdU epitopes and incubate fotr 1 hour at 37°. Then an immunofluorescent 
staining with fluorochrome conjugated (FITC) anti-BrdU was performed on 
cultured cell, which were analyzed by flow cytometry. 
Flow cytometry analysis. FITC-conjugated mAbs to CD11c, CD44, CD25, 
CD4, and Pan B (B220); PE-conjugated mAbs to CD14, CTLA-4 (CD152), 
CD40, VLA-4 (CD49d), ICAM-1 (CD54), OX-40, CD8, γδ, and NK; and 
allophycocyanin-conjugated mAbs to CD45RB and CD4 were all purchased 
from BD Biosciences — Pharmingen. Isolated spleens and lymph nodes 
were prepared for flow cytometry by incubating cells with the appropriate 
Abs or control isotype–matched Abs followed by PBS washes. Data 
collection and analyses were performed on a FACScalibur flow cytometer 
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(BD Biosciences — Immunocytometry Systems). FITC-anti-human-CD4 
and PE-anti-human-CD25 were from BD Pharmingen; the anti-human 
Foxp3 staining set was from eBiosciences (San Diego, CA)..  
Western blot and biochemical analyses. Total cell lysates were obtained in 
50 mM HEPES (pH 7.5), 250 mM NaCl, 1 mM EDTA, 1.0% Triton X-100, 
10 mM sodium fluoride, 1 mM sodium orthovanadate, and 2 µg/ml each of 
aprotinin, leupeptin, and pepstatin. Total proteins (50 µg) from each lysate 
were subjected to SDS-PAGE under reducing conditions. After 
electrophoresis, proteins were transferred onto a nitrocellulose filter 
membrane (Protan; Schleicher & Schuell BioScience) using a Trans-Blot 
Cell (Bio-Rad Laboratories) and transfer buffer containing 25 mM Tris, 192 
mM glycine, and 20% methanol. Membranes were placed in 5% nonfat milk 
in PBS plus 0.5% Tween 20 (PBST) at 4°C for 2 hours to block the 
nonspecific binding sites. Filters were incubated with specific Abs before 
being washed 3 times in PBST and then incubated with a peroxidase-
conjugated secondary Ab (Amersham Biosciences). After further washing 
with PBST, peroxidase activity was detected by using the ECL system 
(Amersham Biosciences). The Abs used were the following: anti-p27Kip-1, 
anti–STAT6, and anti–phosphorylated STAT6 (Y641; all from Cell 
Signaling Technology Inc.); anti-ERK1/2 and anti–phosphorylated ERK1/2 
(Santa Cruz Biotechnology Inc.); and anti-Foxp3 (eBioscience). The filters 
were also probed with an anti-tubulin Ab (Sigma-Aldrich) to normalize the 
amount of loaded protein. All filters were quantified by densitometric 
analysis of the bands utilizing the program ScionImage (version 1.63 for 
Mac; Scion Corp. Inc.)  
Confocal microscopy was performed in parallel with proliferation and 
biochemistry at 1 hr and 36 hr on 98% pure Treg cells and CD4+CD25− cells. 
Cells were washed in PBS and 104 cells were seeded on multitest slide (ICN 
Biomedicals Inc., Aurora, OH), air-dried and fixed for 1 min in methanol, 
washed in PBS, permealized in PBS containing 0.2% Triton X-100 for 3 
min, and incubated in blocking solution (PBS 1% BSA) for 1 hr. Cells were 
then washed three times in PBS and incubated overnight at 4°C with 
primary antibodies (rabbit polyclonal anti-leptin and mouse anti-ObR mAb, 
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both from Santa Cruz Biotechnology Inc.) diluted 1:100 in blocking 
solution, washed in PBS, and incubated with the secondary antibody (goat 
anti-rabbit 488 and goat anti-mouse 543, both from Molecular Probes Inc.) 
for 1 hr at room temperature diluted 1:100 in blocking solution, washed in 
PBS, and finally mounted in PBS/Glycerol 1:1. Immunofluorescence 
analysis was performed with a confocal laser scanner microscope Zeiss 
LSM 510. The wavelength of the Argon ion laser was set at 488 nm; that of 
the HeNe laser was set at 543 nm. Fluorescence emission was revealed by 
BP 505–530 band pass filter for Alexa Fluor 488 and by BP 560-615 band 
pass filter for Alexa Fluor 543. Double-staining immunofluorescence 
images were acquired simultaneously in the green and red channels at a 
resolution of 1024 × 1024 pixels. 
Statistics. Analyses were performed using Mann-Whitney U test (for 
unpaired 2-group analysis) and Kruskal-Wallis ANOVA test (for analysis of 
3 or more groups). Results are expressed as mean ± SD; P values less than 
0.05 were considered statistically significant. 
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DISCUSSION 
 
Over the last few years the intricate interaction between immune system and 
adipose tissue or neuroendocrine system has been recognized. These systems 
influence reciprocally through the production of mediators such as leptin, the 
product of the obese gene (ob). So it has been suggested that the adipose tissue 
is not only a mere site of lipid and energy storage, but can be considered as an 
“immune-related” organ producing a series of molecules named adipokines. 
Among these, leptin seems to play a pivotal role in the regulation of several 
neuroendocrine and immune functions. 
Previous studies by our group and others have shown the relevance of leptin in 
the pathogenesis of EAE (110-112). In particular, it has been previously 
reported that ob/ob mice are resistant to induction of the disease and leptin 
replacement was able to revert this state of resistance into a susceptible one. 
(110). Furthermore in wild-type, EAE-susceptible controls, a surge of serum 
leptin precedes acute EAE clinical onset, which correlates with inflammatory 
anorexia and disease susceptibility (111). In this study, we show that in vivo 
neutralization of leptin is effective at blocking initiation, progression, and 
clinical relapses of EAE, an animal model of MS. 
We and others have previously reported that in the CNS of EAE mice, both 
infiltrating T cells and neurons express high levels of leptin during the acute 
phase of the disease, and the degree of leptin expression within the lesions 
correlates with CNS inflammatory score and disease severity (111). Because of 
the possibility of an autocrine loop, sustaining autoreactive Th1 lymphocytes 
proliferation in EAE ,we analyzed the reactivity and the modulation of immune 
response in leptin-neutralized mice. More in detail, we investigated the DTH 
response as well as T cell proliferation and cytokine secretion in response to 
PLP139–151 in treated mice versus controls. Anti-leptin–treated animals showed 
reduced DTH and T cell proliferative responses to PLP139–151 peptide 
associated with a Th2/regulatory-type cytokine shift, characterized by the 
secretion of IL-4 and IL-10. This evidence was also supported by increased 
expression levels of the regulatory T cell master gene Foxp3 in CD4+ T cells 
from mice with EAE. 
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It is interesting to note that in vivo leptin neutralization differentially affected 
proliferative responses and regulatory cytokine switch during polyclonal anti-
CD3 stimulation. Indeed, while we observed a reduction of proliferation and a 
Th2/regulatory cytokine switch toward PLP139–151, anti-CD3 polyclonal 
stimulation was only affected in terms of cytokine secretion and not of 
proliferative response at the relatively low doses of leptin blockers utilized in 
vivo. The evidence that leptin itself differentially influences polyclonal versus 
antigen-specific proliferation and cytokine secretion may account for these 
apparently contrasting effects (130). On the other hand, it is also possible to 
speculate that leptin neutralization–induced perturbations of the cytokine 
milieu during antigen-specific stimulation may preferentially modulate 
cytokine profile rather than proliferative responses induced by anti-CD3. 
Leptin blockade also affected expression of ICAM-1, OX-40, and VLA-4 on 
CD4+ T cells. Intercellular adhesion molecule (ICAM)-1, or CD54, is a 
member of the immunoglobulin superfamily that binds to lymphocyte function-
associated antigen-1 and macrophage-1 antigen. ICAM-1/LFA-1/Mac-1 
interaction may be involved in both activation and extravasation of leukocytes. 
To determine the roles of ICAM-1 in the development of autoimmune disease, 
Samoivola et al studied experimental autoimmune encephalomyelitis (EAE) in 
mice deficient in ICAM-1 (131). They found that T cell proliferation and TH1-
type cytokine production in response to myelin antigen were significantly 
reduced in ICAM-1-deficient mice, whereas TH2-type cytokine IL-10 was 
increased, resulting in a significantly attenuated EAE, characterized by 
markedly reduced spinal cord T cell infiltration. These results suggest that 
ICAM-1 is involved in the activation of autoreactive Th1 cells and plays an 
important role in down-regulating autoimmune inflammation in the central 
nervous system.. 
In particular, in our results, reduced expression of ICAM-1 observed in leptin-
neutralized mice, was consistent with our previous findings, showing that 
leptin treatment increases surface expression of this adhesion molecule on T 
cells (110). This finding suggested the possibility that neutralization of leptin 
directly affects the cognate interaction leading to reactive and/or autoreactive T 
cell activation. Moreover, marked reduction of OX-40 was also observed after 
leptin blockade. OX-40 is an important costimulatory molecule with pro-
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survival activity for CD4+ T cells, and signaling through this molecule breaks 
peripheral T cell tolerance. The OX-40 protein was selectively up-regulated on 
encephalitogenic myelin basic protein (MBP)-specific T cells at the site of 
inflammation, during the onset of experimental autoimmune encephalomyelitis 
(EAE). An OX-40 immunotoxin was used by Weinberg et al. to target and 
eliminate MBP-specific T cells within the central nervous system without 
affecting peripheral T cells (132). When injected in vivo, the OX-40 
immunotoxin bound exclusively to myelin-reactive T cells isolated from the 
CNS, which resulted in amelioration of EAE. The same authors also showed 
that in vivo administration of soluble OX-40R at the onset of actively induced 
or adoptively transferred EAE reduced ongoing signs of disease, and the mice 
recovered more quickly from acute disease (116). The data imply that OX-40L, 
expressed by CNS-derived APC, acts to provide an important costimulatory 
signal to EAE effector T cells found within the inflammatory lesions. In this 
context our data suggest that leptin may affect expression of key molecules on 
T lymphocytes involved in the mechanisms of immune tolerance, modulating 
the expression of OX-40 as well as ICAM-1. Surprisingly, we also observed 
that leptin neutralization induced increased expression of VLA-4, the α4β1 
integrin, shown to play an integral part in the homing and migration of cells 
that induce EAE. However, experimental evidence has shown that 
administration of anti–VLA-4 ameliorated EAE only if it was initiated before 
disease onset, whereas treatment during acute disease exacerbated EAE and 
enhanced the accumulation of T cells in the CNS (118). Therefore, we are 
tempted to hypothesize that the induction of VLA-4 on CD4+ T cells after 
leptin neutralization could be associated in part with an increased cell 
capability to migrate into the CNS and produce regulatory cytokines able to 
downmodulate EAE. Of note, these data are in agreement with other findings 
showing that adhesion molecules are increased on regulatory T cells in 
experiments of protection from EAE (133, 134). 
To further address, at the biochemical level, whether in vivo leptin 
neutralization interferes with the signalling capacity of autoreactive T cells, we 
analyzed several molecular pathways associated with T cell anergy/activation 
and cytokine switch (14–18). We found that CD4+ T cells from mice treated 
with leptin antagonists showed hyporesponsiveness to PLP139–151 peptide, 
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which was indicated by accumulation of p27Kip-1. Boussiotis et al., using 
anergic human T-cell clones and tolerant alloreactive mouse T cells, that do not 
induce graft-versus-host disease, showed that p27kip1 cyclin-dependent kinase 
inhibitor is an essential regulator responsible for the blockade of clonal 
expansion of anergic T cells in vitro and in vivo. Moreover, in anergic cells, 
p27kip1 associates with the c-Jun co-activator JAB1, resulting in defective 
transactivation of AP-1 and interleukin 2 transcription. Therefore, 
pharmacological agents that up-regulate the expression or prevent the 
degradation of p27kip1, during antigen recognition, should be part of new 
therapeutic strategies to induce antigen-specific T-cell unresponsiveness. So 
the effect mediated by leptin neutralization on p27kip1 expression can lead us 
to think to leptin as a potential target to induce T cell anergy.  (119, 122, 135). 
Activation of T cells via the TCR and other co-stimulatory receptors triggers a 
number of signalling cascades. Among them, the Ras-activated Raf-mitogen-
activated protein/extracellular signal-related kinase (ERK) kinase (MEK)-ERK 
signaling cascade has been demonstrated to be crucial for both T cell 
development and activation. It has previously been demonstrated that high 
doses of Ag or anti-CD3 mAb are able to induce in T cells a non-responsive 
state to subsequent treatment with cytokines, such as IL-2. The precise 
biochemical mechanisms underlying this effect are not fully characterized. In 
1999 Chen et al. demonstrated that cytokine non-responsiveness is 
accompanied by the induction of the cyclin-dependent kinase inhibitor p21Cip1 
that is mediated, at least in part, by the activation of the Raf-MEK-ERK 
pathway (136). Furthermore, they demonstrated that selective activation of the 
Raf-MEK-ERK signalling pathway in T cells is sufficient to induce cytokine 
non-responsiveness in both a T cell clone and naive primary T cells. In this 
case, non-responsiveness is accompanied by the induction of p21Cip1 and the 
prevention of p27Kip1 down-regulation, leading to inhibition of cyclin E/cyclin-
dependent kinase 2 activity (136). These data suggest that anti-CD3 mAb-
induced cytokine non-responsiveness may be a consequence of hyperactivation 
of the Raf-MEK-ERK pathway, leading to alterations in the expression of key 
cell cycle regulators. We also found that the hyporesponsive state induced by 
leptin antagonism was associated with marked increase of ERK1/2 
phosphorylation, confirming involvement of ERK1/2 in the improvement of 
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EAE (136). It is interesting to observe that our findings with leptin antagonism 
seem to involve pathways affected by statins, cholesterol-lowering drugs that 
have recently been shown to reduce production of leptin by adipocytes (137), 
promote Th2 responses, and improve EAE (138) by disabling downregulation 
of p27Kip-1 and upregulating phosphorylation of ERK1/2 (139). Experimental 
autoimmune encephalomyelitis (EAE) is mediated by myelin-specific CD4(+) 
T cells secreting Th1 cytokines, while recovery from disease is associated with 
expression of Th2 cytokines. Investigations into the role of individual 
cytokines in disease induction have yielded contradictory results.  Animals 
with targeted deletion of the STAT4 or STAT6 genes were generated to 
determine the role of these signalling molecules in EAE. The STAT4 pathway 
controls the differentiation of cells into a Th1 phenotype, while the STAT6 
pathway controls the differentiation of cells into a Th2 phenotype. Indeed 
Chitnis et al demonstrated that mice deficient in STAT4 are resistant to the 
induction of EAE, with minimal inflammatory infiltrates in the central nervous 
system. In contrast, STAT6-deficient mice, which have a predominantly Th1 
phenotype, experience a more severe clinical course of EAE as compared with 
wild-type or STAT4 knockout mice. Finally, we also observed at the 
biochemical level the induction of phosphorylation of the STAT6 transcription 
factor, after leptin neutralization. As said before, this molecule is a factor well 
known to be able to induce the transcription of IL-4 and associated with a 
classical Th2/regulatory-type cytokine response during EAE (123). So, our 
results confirm the induction of a regulatory phenotype, induced by leptin 
neutralization, in the autoreactive T cells infiltrating CNS during EAE.   
In conclusion, in the first part of this study, we report that leptin neutralization 
was able to improve clinical onset, progression, and clinical relapses of both 
actively induced and passively transferred EAE. This effect was associated 
with marked inhibition of DTH reaction against PLP139–151 peptide, CD4+ T 
cell hyporesponsiveness, and increased IL-4 and IL-10 production against 
myelin antigens. Foxp3 expression was also induced on CD4+ T cells in leptin-
neutralized mice, suggesting the induction of a regulatory phenotype. At the 
biochemical level, T cell hyporesponsiveness might be explained by the failure 
to downmodulate the anergy factor p27Kip-1 and by the increase in the tyrosine 
phosphorylation levels of ERK1/2 and STAT6. Taken together, our results 
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provide a framework for leptin-based intervention in EAE and identify 
molecules with possible therapeutic potential for the disease. 
In the second part of this study, to evaluate whether clinical improvement of 
EAE, induced by leptin neutralization, could be ascribed to the effect of this 
kind of treatment on the homeostasis and function of  regulatory T cells (a 
specific cellular subset, known to control the mechanisms of immune 
tolerance), we performed a series of experiments to check and confirm a 
possible link between leptin and/or its neutralization and Tregs. The supporting 
evidence for the hypothesis of a direct interaction between leptin and Tregs 
base on some results we recently obtained in our laboratory, in which we 
showed that leptin deficiency associates with resistance to autoimmunity, 
higher frequency of Tregs and increased susceptibility to infections; we also 
demonstrated the presence of an inverse correlation between circulating Tregs 
and serum leptin levels in naive-to-treatment multiple sclerosis patients. 
In this study we establish a unique link between Treg cells and leptin by 
showing that leptin can modulate the hyporesponsiveness and proliferation of 
Treg cells both in vitro and in vivo. Freshly isolated human Treg cells express 
high amounts of ObR and produce substantial amounts of leptin that are 
responsible for an autocrine inhibitory loop that constrains the expansion of 
Treg cells (data confirmed in serum and leptin-free conditions). Although leptin 
neutralization inhibits the proliferation of effector CD4+CD25− T cells, this 
condition leads to an expansion of the Treg cells, which maintain their 
suppressive phenotype in the resting phase. The opposite effects of leptin 
blockade on CD4+CD25− T cells and Treg cells associate with a differential 
expression of intracellular leptin and cell-surface ObR in the two cell subsets. 
It must be noted that in our experimental system, the culture media 
supplemented with human serum contained low—albeit significant—
concentrations of human leptin (0.5–1 ng/ml in the 5% human serum [HS]/95% 
RPMI). The contribution of HS-derived leptin versus Treg cell-derived leptin 
was analyzed in cultures with three different serum-free media—all tested for 
the absence of leptin. The anti-leptin-induced expansion of the Treg cells in 
serum-free conditions indicated that the Treg cell-derived leptin was sufficient 
to act as negative signal for the expansion of the Treg cells. It is possible to 
speculate that a leptin-mediated negative autocrine loop may operate on Treg 
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cells, because both freshly isolated and cultured Treg cells stain positive for and 
secrete leptin. On the other hand, the leptin present in the culture medium and 
secreted by the CD4+CD25− T cells could act as a positive signal for T cell 
proliferation. These differential effects induced by leptin could rely upon the 
different ObR levels and leptin secretory capacity, which would ultimately 
affect the intracellular signaling differentially. 
Our Treg cells were cultured in medium supplemented with 5% HS because 
fetal calf serum (FCS) is rich in bovine leptin (10–20 ng/ml in RPMI 10% 
FCS) that is not neutralized by human leptin mAb (data not shown). We also 
found that 10% FCS abrogated the effects induced by human leptin mAb on 
human Treg cells (data not shown). Therefore, it was crucial, for efficient leptin 
neutralization, to avoid exposure to FCS for the ObR-expressing Treg cells. The 
same issue has to be taken into account had the Treg cells been isolated by 
positive selection and thus undergone repeated steps of FCS exposure 
compromising leptin neutralization. Moreover, we also noted that Treg cells 
isolated by positive selection with anti-CD25 mAb (either by FACS or 
magnetic bead cell sorting) had a reduced capacity to proliferate in vitro after 
leptin neutralization when the anti-CD25 mAb was not removed from the cell 
surface after isolation. The reasons for an interference of the anti-CD25 mAb 
with leptin neutralization process and Treg cell expansion are currently being 
investigated and might include an interference with IL-2 signaling, a functional 
inactivation of the Treg cells by the anti-CD25 mAb recently demonstrated 
(140) and an influence on the kinetics and the degree of leptin secretion by the 
Treg cells. In any case, detachment of the anti-CD25 mAb after cell isolation 
completely eliminates possible problems of proliferation for the anti-leptin-
treated stimulated Treg cells. 
Naturally occurring CD25+CD4+ regulatory T cells are engaged in the 
maintenance of immunological self-tolerance and down-regulation of various 
immune responses (129). Recent studies with mice showed that Foxp3, which 
encodes the transcription factor Scurfin, is a master regulatory gene for the 
development and function of CD25+CD4+ regulatory T cells. The FOXP3 
gene and its protein product were preferentially expressed in peripheral 
CD25+CD4+ T cells, in particular CD25+CD45RO+CD4+ T cells in normal 
individuals and, interestingly, in some human T cell leukemia virus type 1-
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infected T cell lines, which constitutively express CD25. Ex vivo retroviral 
gene transfer of FOXP3 converted peripheral CD25-CD45RO-CD4+ naive T 
cells into a regulatory T cell phenotype similar to CD25+CD4+ regulatory T 
cells. For example, FOXP3-transduced T cells exhibited impaired proliferation 
and production of cytokines including IL-2 and IL-10 upon TCR stimulation, 
up-regulated the expression of regulatory T cell-associated molecules such as 
CD25 and CTL-associated antigen-4 and suppressed in vitro proliferation of 
other T cells in a cell-cell contact-dependent manner. Thus, human FOXP3 is a 
crucial regulatory gene for the development and function of CD25+CD4+ 
regulatory T cells, and can be used as their reliable marker. In our experimental 
conditions Foxp3 was induced in leptin-neutralized Treg cells at late time points 
(12 hr), supporting the evidence that removal of leptin from culture medium 
not only expanded the Treg cells but also allowed the maintenance of their 
suppressive phenotype. The phenomenon might possibly be ascribed to the 
increased IL-2 secretion induced by leptin neutralization, because others have 
shown that IL-2 is capable of upregulating Foxp3 expression in human Treg 
cells (141). 
Incidentally, this study also describes a novel strategy to expand human 
peripheral Treg cells, via leptin neutralization, although this approach needs to 
be further investigated. Tang et al. already described a robust method to expand 
antigen-specific Tregs from autoimmune-prone nonobese diabetic mice: briefly 
purified CD4+ CD25+ Tregs were expanded up to 200-fold in less than 2 
weeks in vitro, using a combination of anti-CD3, anti-CD28, and interleukin 2 
(142). The expanded Tregs express a classical cell surface phenotype and 
function both in vitro and in vivo to suppress effector T cell functions. So 
current strategies to expand Treg cells generally employ ex vivo addition of 
cytokines to cultured cells during TCR stimulation (142, 143). Because 
neutralization of the leptin present in human serum of tissue cultures and of 
leptin produced by Treg cells may be sufficient to determine an expansion of the 
Treg cells, it might be possible that leptin neutralization, in addition with 
exogenous IL-2, may improve the protocols of expansion for Treg cells. We are 
currently investigating this possibility. 
In vivo studies in leptin-deficient ob/ob mice show higher percentage and 
absolute number of circulating Treg cells. They can expand up to 90% in vivo in 
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normal nonlymphopenic hosts by day 28 after transfer (126). Adoptive transfer 
experiments of CFSE-labeled Treg cells from WT mice into leptin-deficient 
ob/ob mice showed a significant in vivo expansion of Treg cells. It is also 
noteworthy that chronic leptin deficiency allows higher expansion of Treg cells 
when compared with acute leptin neutralization induced by leptin Ab (the 
percentage of proliferating Treg cells in ob/ob mice was always higher than that 
observed in leptin-neutralized WT mice). Importantly, in vivo leptin 
neutralization also determined an increased Foxp3 expression in the Treg cells, 
suggesting maintenance of their suppressive phenotype after expansion in vivo. 
The finding that leptin can act as a negative signal for the proliferation of Treg 
cells envisions new possibilities of anti-leptin-based approaches for the 
immunotherapy of conditions characterized by low numbers of Treg cells. 
Leptin might act as an endogenous “sensing” factor linking the environment 
(availability of nutrients) to circulating Treg cell number. Because nutritional 
deprivation increases susceptibility to infection and associates with 
amelioration of clinical manifestations of autoimmunity (144, 145), it will be 
important to address how this relates to the influence of leptin on Treg cells and 
whether anti-leptin-based intervention can be applied to tune cognate T cell 
responses in immune regulation. 
There are still many questions concerning the role of several molecules, 
including leptin and other adipokines, at the interface between metabolism and 
immunity in the regulation of these two systems. Taken together these results 
allow us to imagine a scenario of a huge number of autoimmune settings where 
Tregs are isolated from patients either during remission (as would be the case for 
systemic lupus erythematosus or multiple sclerosis) or soon after disease onset 
(as would be the case for T1D). The cells would be expanded and reintroduced 
at the time of maximal disease activity to moderate the inflammatory response. 
In some cases this could be combined with rapamycin, anti-CD3, or other drugs 
that cause deletion of the pathogenic cells without affecting the Tregs . Together, 
these therapies could both reduce the short-term pathogenic responses while 
reinstating a homeostatic balance for long-term tolerance induction and recent 
studies aim at developing a procedure to selectively and reproducibly expand 
antigen-specific Tregs from polyclonal populations for therapeutic use. 
Significant leaps of knowledge have been done in recent years in expanding the 
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field of adipobiology and adipopharmacology of leptin. While new information 
is unveiling the complexity connecting metabolism and immunity, further 
research is still needed. This should consider the adipose tissue an active 
participant in the regulation of essential body process, with prominent roles, 
particularly in the balance of inflammation and immune homeostasis. 
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CONCLUSIONS 
In the first part of this study we analyzed the possible effects of leptin blockade 
on the pathogenesis of Experimental Autoimmune Encephalomyelitis (EAE), 
the animal model of human Multiple Sclerosis. More in detail, we reported that 
leptin neutralization was able to improve clinical onset, progression, and 
clinical relapses of both actively induced and passively transferred EAE. This 
effect was associated with marked inhibition of DTH reaction against PLP139–
151 peptide, CD4+ T cell hyporesponsiveness, and increased IL-4 and IL-10 
production against myelin antigens. Foxp3 (a selective marker for regulatory T 
cells, a cellular subpopulation known to be involved in the control of immune 
tolerance) expression was also induced on CD4+ T cells in leptin-neutralized 
mice, suggesting the induction of a regulatory phenotype. At the biochemical 
level, T cell hyporesponsiveness, induced by leptin neutralization, might be 
explained by the failure to downmodulate the anergy factor p27Kip-1 and by the 
increase in the tyrosine phosphorylation levels of ERK1/2 and STAT6 (a factor 
well known to be able to induce the transcription of IL-4 and associated with a 
classical Th2/regulatory-type cytokine response during EAE). We also 
evaluated whether clinical improvement of EAE, induced by leptin 
neutralization, could be ascribed to a direct effect of this kind of treatment on 
the homeostasis and function of  regulatory T cells.  
We report in this study that leptin can act as a negative signal for the 
proliferation of human naturally occurring Foxp3+CD4+CD25+ regulatory T 
(Treg) cells. Freshly isolated Treg cells expressed high amounts of leptin 
receptor (ObR) and produced substantial amounts of leptin, that are responsible 
for an autocrine inhibitory loop that constrains the expansion of Treg cells (data 
confirmed in serum and leptin-free conditions). Although leptin neutralization 
inhibits the proliferation of effector CD4+CD25− T cells, in vitro neutralization 
with leptin monoclonal antibody (mAb), during anti-CD3 and anti-CD28 
stimulation, resulted in Treg cell proliferation and these cells, that proliferated 
in the presence of leptin mAb, had increased expression of Foxp3 and retained 
partial suppressive capacity, which attains full activity when they enter the 
resting phase. The opposite effects of leptin blockade on CD4+CD25− T cells 
and Treg cells associated with a differential expression of intracellular leptin 
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and cell-surface ObR in the two cell subsets. We also showed that mouse Treg 
cells expanded in vivo more robustly and earlier (day 4 and day 7 after 
transfer) when adoptively transferred into leptin-neutralized WT mice, or leptin 
deficient mice. Moreover leptin-deficient mice have increased numbers of Treg 
cells that can be reduced by administration of leptin, confirming the role of 
leptin as a negative regulator of Tregs homeostasis in constraining their 
proliferative response. Taken together these results suggest a potential for 
innovative therapeutic leptin-based interventions in immune and autoimmune 
diseases, since they describe a novel strategy to expand human peripheral Treg 
cells, on one hand, and inhibit autoreactive T cells proliferation, on the other,  
via leptin neutralization. 
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